<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006635</article-id><article-id pub-id-type="pmc">PMC11860126</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics17020268</article-id><article-id pub-id-type="publisher-id">pharmaceutics-17-00268</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>X-Ray Irradiation Induces Oxidative Stress and Upregulates Intestinal Nrf2-Mrp2 Pathway, Leading to Decreased Intestinal Absorption of Valsartan</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Teng</surname><given-names>Yunhua</given-names></name><xref rid="af1-pharmaceutics-17-00268" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Jiaojiao</given-names></name><xref rid="af2-pharmaceutics-17-00268" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Junxia</given-names></name><xref rid="af2-pharmaceutics-17-00268" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Liang</surname><given-names>Bohan</given-names></name><xref rid="af1-pharmaceutics-17-00268" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Aijie</given-names></name><xref rid="af1-pharmaceutics-17-00268" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yanjie</given-names></name><xref rid="af1-pharmaceutics-17-00268" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Dong</surname><given-names>Shiqi</given-names></name><xref rid="af1-pharmaceutics-17-00268" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Fan</surname><given-names>Huirong</given-names></name><xref rid="af1-pharmaceutics-17-00268" ref-type="aff">1</xref><xref rid="c1-pharmaceutics-17-00268" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Vandamme</surname><given-names>Thierry</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-17-00268"><label>1</label>Key Laboratory of Radiopharmacokinetics for Innovative Drugs, Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, China; <email>tengyh847@163.com</email> (Y.T.); <email>a1026894769@163.com</email> (B.L.); <email>zhangaijie1986@163.com</email> (A.Z.); <email>15102274665@163.com</email> (Y.L.); <email>dongsq1314@126.com</email> (S.D.)</aff><aff id="af2-pharmaceutics-17-00268"><label>2</label>Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China; <email>19861402016@163.com</email> (J.M.); <email>jxzhang1204@163.com</email> (J.Z.)</aff><author-notes><corresp id="c1-pharmaceutics-17-00268"><label>*</label>Correspondence: <email>fanhuirong@irm-cams.ac.cn</email></corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>268</elocation-id><history><date date-type="received"><day>08</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>13</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>14</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background:</bold> It has been documented that radiation can influence the pharmacokinetics of chemotherapy drugs, yet the underlying mechanisms remain poorly understood. In clinical practice, a considerable number of cancer patients undergo radiotherapy, and those with comorbid hypertension required antihypertensive drugs, including valsartan, an angiotensin II receptor blocker. However, there is no research investigating whether radiotherapy poses a risk of altering the pharmacokinetics. <bold>Objective:</bold> The objective of this study is to investigate the impact of X-ray abdominal irradiation on the pharmacokinetics of valsartan and to preliminarily elucidate the underlying mechanism. <bold>Methods:</bold> The pharmacokinetics of valsartan after X-ray irradiation was investigated in rats and in vitro by detecting the concentration of valsartan in biological samples by LC-MS/MS. The oxidative stress in the intestine and the mRNA expression of partial transporters and Nrf2 in the liver and small intestine were detected by biochemical reagent kit or RT-qPCR. <bold>Results</bold>: In vivo studies showed that X-ray irradiation resulted in a significant decrease in the AUC and C<sub>max</sub> of valsartan, and the cumulative fractional excretion of valsartan in bile and urine, although there was no significant change in fecal excretion. In vitro studies showed that the uptake of valsartan by both intestine and Caco-2 cells decreased after irradiation, and the cellular uptake could be restored by Mrp2 inhibitor MK571. The levels of GSH, SOD, and CAT in the intestine decreased after irradiation. The mRNA expressions of Mrp2 and P-gp in the intestine or Caco-2 cells were significantly upregulated after irradiation while there was a downregulation of Mrp2 and oatp1b2 in liver. Nrf2 and HO-1 in the intestine were also significantly upregulated, which clarified the involvement of Mrp2 and the possible molecular mechanism. <bold>Conclusions:</bold> Abdominal X-ray irradiation can cause oxidative stress and upregulate intestinal Mrp2, which may be related to oxidative stress and upregulation of Nrf2, reducing intestinal absorption of valsartan and leading to a significant decrease in the blood concentration of valsartan.</p></abstract><kwd-group><kwd>x-ray irradiation</kwd><kwd>pharmacokinetics</kwd><kwd>oxidative stress</kwd><kwd>valsartan</kwd><kwd>drug absorption</kwd><kwd>Mrp2</kwd></kwd-group><funding-group><award-group><funding-source>Tongliao Science and Technology Projects Fund</funding-source><award-id>TL2023YF0101</award-id></award-group><award-group><funding-source>National Natural Science Foundation of China</funding-source><award-id>82204509</award-id></award-group><funding-statement>This work is supported by the Young Scientists Fund of the National Natural Science Foundation of China (No. 82204509) and Tongliao Science and Technology Projects Fund (No. TL2023YF0101).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-17-00268"><title>1. Introduction</title><p>In recent years, some studies have found that ionizing radiation, including X-rays and gamma rays, can affect the pharmacokinetics of some drugs in animals [<xref rid="B1-pharmaceutics-17-00268" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceutics-17-00268" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceutics-17-00268" ref-type="bibr">3</xref>]. For example, Hsieh et al. reported that local irradiation could affect the pharmacokinetics of 5-fluorouracil in rats [<xref rid="B3-pharmaceutics-17-00268" ref-type="bibr">3</xref>], resulting in a decrease in the area under the plasma drug concentration&#x02013;time curve (AUC) and an increase in the clearance rate (CL) of 5-fluorouracil. In addition, the excretion of the parent drug in the bile increased, whereas there was a decrease observed in the metabolites. Our laboratory has also reported the impact of X-ray irradiation on drug pharmacokinetics in rats, including the reduction in plasma area under the curve (AUC) and excretion of apatinib in rats [<xref rid="B4-pharmaceutics-17-00268" ref-type="bibr">4</xref>]. Additionally, we observed a decrease in renal excretion of bestatin in rats, resulting in increased body accumulation and blood drug concentration [<xref rid="B5-pharmaceutics-17-00268" ref-type="bibr">5</xref>]. This phenomenon, in which radiation affects the absorption, distribution, metabolism, or excretion of drugs in the body, leading to changes in the pharmacokinetic characteristics of drugs, is called radiation pharmacokinetics [<xref rid="B6-pharmaceutics-17-00268" ref-type="bibr">6</xref>] (hereinafter referred to as RT-PK). In clinical practice, the co-administration of radiotherapy and drugs in cancer patients may result in RT-PK, which can potentially alter the pharmacokinetics of the drugs utilized. The occurrence of RT-PK may lead to an elevation in drug exposure or accumulation within the body, thereby potentially inducing more severe toxic side effects. Conversely, it could also result in a reduction in drug efficacy. Consequently, further investigations into the phenomenon of RT-PK and its underlying mechanisms are warranted.</p><p>According to the &#x0201c;China Cardiovascular Health and Disease Report 2023&#x0201d; [<xref rid="B7-pharmaceutics-17-00268" ref-type="bibr">7</xref>], the prevalence of hypertension in China has reached a staggering 245 million individuals. Simultaneously, there exists an overlap between this population and the considerable number of cancer patients in China [<xref rid="B8-pharmaceutics-17-00268" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceutics-17-00268" ref-type="bibr">9</xref>]. Firstly, there exist shared risk factors between hypertension and cancer, including advanced age [<xref rid="B10-pharmaceutics-17-00268" ref-type="bibr">10</xref>], tobacco use [<xref rid="B11-pharmaceutics-17-00268" ref-type="bibr">11</xref>], diabetes [<xref rid="B12-pharmaceutics-17-00268" ref-type="bibr">12</xref>], and obesity [<xref rid="B13-pharmaceutics-17-00268" ref-type="bibr">13</xref>], among others. Secondly, hypertension is a common concomitant disease in cancer patients [<xref rid="B11-pharmaceutics-17-00268" ref-type="bibr">11</xref>,<xref rid="B14-pharmaceutics-17-00268" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceutics-17-00268" ref-type="bibr">15</xref>]. In addition to hypertension associated with certain neoplasms, such as pheochromocytoma [<xref rid="B14-pharmaceutics-17-00268" ref-type="bibr">14</xref>], secondary hypertension is usually triggered or exacerbated by cancer treatment drugs [<xref rid="B16-pharmaceutics-17-00268" ref-type="bibr">16</xref>], especially vascular endothelial growth factor inhibitors (VEGFIs) [<xref rid="B11-pharmaceutics-17-00268" ref-type="bibr">11</xref>,<xref rid="B17-pharmaceutics-17-00268" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-17-00268" ref-type="bibr">18</xref>]. For instance, clinical studies have shown that the incidence of hypertension associated with bevacizumab treatment ranges from 26% to 55% [<xref rid="B18-pharmaceutics-17-00268" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceutics-17-00268" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceutics-17-00268" ref-type="bibr">20</xref>]. Inadequate management of hypertension also heightens the risk of cardiotoxicity resulting from cancer treatment [<xref rid="B21-pharmaceutics-17-00268" ref-type="bibr">21</xref>] and increases the mortality risk associated with cardiovascular disease [<xref rid="B9-pharmaceutics-17-00268" ref-type="bibr">9</xref>,<xref rid="B22-pharmaceutics-17-00268" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceutics-17-00268" ref-type="bibr">23</xref>]. Therefore, it is imperative to enhance both prevention and management strategies for hypertension in individuals with cancer. The rational utilization of antihypertensive medications can effectively assist cancer patients in managing blood pressure and reducing the incidence of cardiovascular events [<xref rid="B9-pharmaceutics-17-00268" ref-type="bibr">9</xref>,<xref rid="B24-pharmaceutics-17-00268" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceutics-17-00268" ref-type="bibr">25</xref>]. Sartans (angiotensin II receptor blockers, ARBs) can reduce blood pressure by blocking the binding of angiotensin II to its receptor [<xref rid="B26-pharmaceutics-17-00268" ref-type="bibr">26</xref>]. They are the first-line antihypertensive drugs recommended by the European Society of Cardiology [<xref rid="B22-pharmaceutics-17-00268" ref-type="bibr">22</xref>]. ARBs exhibit the characteristics of a stable antihypertensive effect and few adverse reactions, making them suitable for monotherapy or combination therapy in the prevention and treatment of hypertension, including hypertensive conditions in cancer patients [<xref rid="B25-pharmaceutics-17-00268" ref-type="bibr">25</xref>]. This raises the question of whether radiation can induce the RT-PK phenomenon in antihypertensive drugs when these patients receive radiotherapy, thereby affecting the effect of blood pressure control and even the life health of cancer patients.</p><p>The absorption, distribution, metabolism, and excretion of drugs in the body are significantly influenced by transporters and metabolic enzymes. During the RT-PK phenomenon, alterations in the pharmacokinetic processes of drug absorption, distribution, metabolism, and excretion have been observed [<xref rid="B1-pharmaceutics-17-00268" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceutics-17-00268" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceutics-17-00268" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceutics-17-00268" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceutics-17-00268" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceutics-17-00268" ref-type="bibr">6</xref>]. Previous studies suggest that these changes are likely attributable to the impact of radiation on metabolic enzymes [<xref rid="B1-pharmaceutics-17-00268" ref-type="bibr">1</xref>] or transporters [<xref rid="B5-pharmaceutics-17-00268" ref-type="bibr">5</xref>]. However, the mechanism of RT-PK is still poorly understood. Furthermore, ionizing radiation can induce the generation of reactive oxygen species (ROS) [<xref rid="B27-pharmaceutics-17-00268" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceutics-17-00268" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-17-00268" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-17-00268" ref-type="bibr">30</xref>], leading to oxidative stress [<xref rid="B30-pharmaceutics-17-00268" ref-type="bibr">30</xref>]. Oxidative stress involves changes in a series of pathways [<xref rid="B31-pharmaceutics-17-00268" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceutics-17-00268" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceutics-17-00268" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceutics-17-00268" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceutics-17-00268" ref-type="bibr">35</xref>], such as the antioxidant-related pathway Nrf2-ARE [<xref rid="B34-pharmaceutics-17-00268" ref-type="bibr">34</xref>], the inflammation-related pathway PI3K [<xref rid="B31-pharmaceutics-17-00268" ref-type="bibr">31</xref>], etc. Some of these pathways are closely related to the regulation of P-gp [<xref rid="B36-pharmaceutics-17-00268" ref-type="bibr">36</xref>], Mrp2 [<xref rid="B31-pharmaceutics-17-00268" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceutics-17-00268" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceutics-17-00268" ref-type="bibr">33</xref>,<xref rid="B37-pharmaceutics-17-00268" ref-type="bibr">37</xref>], and other transporters [<xref rid="B36-pharmaceutics-17-00268" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceutics-17-00268" ref-type="bibr">37</xref>]. This suggests the possibility that radiation affects transporter expression through oxidative stress. For instance, nuclear factor erythroid 2-related factor 2 (Nrf2), which plays a crucial role in the body&#x02019;s regulation of oxidative stress, also exerts transcriptional regulation on multidrug resistance-associated protein 2 (Mrp2) and can be activated by radiation exposure [<xref rid="B38-pharmaceutics-17-00268" ref-type="bibr">38</xref>]. Our previous study found that abdominal X-ray radiation could affect the pharmacokinetics of various sartans, including valsartan, which was not metabolized in vivo and excreted as the original [<xref rid="B39-pharmaceutics-17-00268" ref-type="bibr">39</xref>]. Valsartan is a substrate of Mrp2 [<xref rid="B40-pharmaceutics-17-00268" ref-type="bibr">40</xref>]. Mrp2 is primarily expressed in the small intestine [<xref rid="B41-pharmaceutics-17-00268" ref-type="bibr">41</xref>], especially in the proximal duodenum and jejunum [<xref rid="B42-pharmaceutics-17-00268" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceutics-17-00268" ref-type="bibr">43</xref>], the hepatocyte canalicular membrane [<xref rid="B44-pharmaceutics-17-00268" ref-type="bibr">44</xref>,<xref rid="B45-pharmaceutics-17-00268" ref-type="bibr">45</xref>], etc. Mrp2 plays a pivotal role in the efflux of numerous drugs (methotrexate [<xref rid="B46-pharmaceutics-17-00268" ref-type="bibr">46</xref>], pravastatin [<xref rid="B47-pharmaceutics-17-00268" ref-type="bibr">47</xref>], and irinotecan [<xref rid="B48-pharmaceutics-17-00268" ref-type="bibr">48</xref>]), phase II metabolites (acetaminophen sulfate [<xref rid="B49-pharmaceutics-17-00268" ref-type="bibr">49</xref>] and resveratrol glucuronide/sulfate [<xref rid="B50-pharmaceutics-17-00268" ref-type="bibr">50</xref>]), and endogenous substances (bilirubin [<xref rid="B51-pharmaceutics-17-00268" ref-type="bibr">51</xref>] and glutathione S-conjugates [<xref rid="B52-pharmaceutics-17-00268" ref-type="bibr">52</xref>]) into extracellular fluid (bile, intestinal fluid, and urine) [<xref rid="B53-pharmaceutics-17-00268" ref-type="bibr">53</xref>]. Consequently, it is closely associated with drug absorption, distribution, and excretion. Therefore, the expression level of Mrp2 may significantly impact valsartan. Additionally, it has been reported that P-glycoprotein (P-gp) can also impact the absorption of valsartan [<xref rid="B54-pharmaceutics-17-00268" ref-type="bibr">54</xref>,<xref rid="B55-pharmaceutics-17-00268" ref-type="bibr">55</xref>]. Valsartan is also a substrate for organic anion-transporting polypeptides 1B1/1B3 (OATP1B1/1B3) [<xref rid="B40-pharmaceutics-17-00268" ref-type="bibr">40</xref>], which are predominantly expressed in the human liver and play a crucial role in drug uptake. Therefore, if ionizing radiation affects the aforementioned transporters, it is highly probable that it will alter the pharmacokinetics of valsartan in vivo.</p><p>In summary, the primary objectives of this study were to investigate the impact of X-ray irradiation on the pharmacokinetics of valsartan and elucidate the underlying mechanism, including the alterations in the expression of valsartan-related transporters and the role of oxidative stress and Nrf2 in these changes. The results of this study could provide some reference basis for regulating the medication of valsartan before and after abdominal radiotherapy in cancer patients with hypertension, and even to predict the RT-PK of other drugs.</p></sec><sec id="sec2-pharmaceutics-17-00268"><title>2. Materials and Methods</title><sec id="sec2dot1-pharmaceutics-17-00268"><title>2.1. Chemicals and Regents</title><p>Valsartan (CAS:137862-53-4), verapamil (CAS:52-53-9), telmisartan (CAS:144701-48-4), and MK571 (CAS:115104-28-4) were purchased from Macklin (Shanghai, China). Acetonitrile and methanol (HPLC grade) were purchased from Concord Technology (Tianjin, China), sodium carboxymethylcellulose (CMC-Na) and ammonium acetate from Aladdin(Shanghai, China), Dulbecco&#x02019;s modified eagle medium (DMEM), basal medium, and fetal bovine serum (FBS) from Gibco (Waltham, MA, USA), and penicillin&#x02013;streptomycin (100&#x000d7;: 10,000 Units) and trypsin from Sigma Aldrich (St. Louis, MO, USA). Triton X-100 and BCA protein concentration assay kits were purchased from Solaibio (Beijing, China), and GSH, SOD, and CAT assay kits were purchased from Nanjing Jianxeng BioEngineering Institute (Nanjing, China). TRIzol reagent was purchased from Invitrogen (Carlsbad, CA, USA).</p></sec><sec id="sec2dot2-pharmaceutics-17-00268"><title>2.2. LC-MS/MS Conditions</title><p>Reverse-phase chromatography was performed under gradient conditions. The separation column used was an InfinityLab Poroshell 120 EC-C18 (2.1 &#x000d7; 50 mm, 2.7-Micron) and its operating temperature was 40 &#x000b0;C. The samples were injected into the system through an autosampler at a volume of 1 &#x003bc;L, and the samples were maintained at 4 &#x000b0;C before injection. The mobile phase was composed of (A) water (containing 1 mM ammonium acetate, 0.05% formic acid, and 5% acetonitrile) and (B) acetonitrile. The flow rate was set to 0.3 mL/min, the elution procedure and mobile phase ratio were 0&#x02013;0.5 min, and 30% B operation was maintained; from 0.5 to 2.0 min, it increased from 30% B to 85% B in 1.5 min; from 2.0 to 4.0 min, running was kept stable at 85% B for 2 min; from 4.0 to 4.1 min, it decreased from 85% B to 30% B within 0.1 min; and from 4.1 to 5.5 min, running was maintained at 30% B.</p><p>The analytes were detected and quantified by tandem mass spectrometry (MS/MS) in positive-ion mode. The ion source was electrospray ionization (ESI), and the detection was performed by a triple quadrupole detector. MS parameters were optimized as follows: the ion spray voltage was 5500 V; the ion source temperature was 550 &#x000b0;C; the curtain gas was 50 psi; the entrance potential (EP) was 12 V; the collision cell exit potential (CXP) was 11 V; the collision energy (CE) was 41 V; the declustering potential (DP) was 38 V; the valsartan ion pair was <italic toggle="yes">m/z</italic> 436.1&#x02192;207.1; and the internal standard (telmisartan) ion pair was <italic toggle="yes">m/z</italic> 515.2&#x02192;276.1.</p></sec><sec id="sec2dot3-pharmaceutics-17-00268"><title>2.3. Method Validation</title><p>A stock solution of 1 mg/mL was obtained by dissolving 10 mg of valsartan/telmisartan standard in 10 mL of methanol and it was stored at &#x02013;20 &#x000b0; C. The valsartan stock solution was diluted with pure methanol to obtain a series of gradient concentration calibration curve working solutions and a quality control working solution. The concentrations of the valsartan calibration curve (including the standard concentration 1&#x02013;7, S1&#x02013;S7) working solutions were as following: 2, 10, 100, 500, 2500, 4000, and 5000 ng/mL. The concentrations of the lower limit of quantification (LLOQ) and quality control (LQC, MQC, and HQC) working solutions were 2, 5, 1000, and 3750 ng/mL, respectively. The stock solution was diluted to 50 ng/mL with pure methanol to obtain the internal standard working solution.</p><p>A total of 50 &#x003bc;L of the prepared valsartan working solution and telmisartan working solution were added to blank rat plasma (50 &#x003bc;L) in turn, and methanol was added as a precipitant to 250 &#x003bc;L. After centrifugation at 16,260&#x000d7; <italic toggle="yes">g</italic> for 10 min, 100 &#x003bc;L of the supernatant was taken for LC-MS/MS analysis. Calibration curve standard samples were also prepared, including double-blank and blank (with IS added) plasma samples.</p><p>According to the guidance principles of &#x0201c;M10: Bioanalytical Method Validation and Sample Analysis&#x0201d;, published by ICH (the International Coordinating Committee for Technical Requirements for Medicinal Products for Human Use) [<xref rid="B56-pharmaceutics-17-00268" ref-type="bibr">56</xref>], combined with the actual requirements for substance quantification in this study, the selectivity, accuracy, precision, and linearity, as well as the extraction recovery and matrix effect of the established LC-MS/MS quantitative analysis method, were validated.</p></sec><sec id="sec2dot4-pharmaceutics-17-00268"><title>2.4. Animals and Treatments</title><p>All animal experiments were approved by the Animal Ethics Committee of the Institute of Radiation Medicine, Chinese Medical Sciences. Male Sprague Dawley (SD) rats (weight 200 &#x000b1; 20 g) were purchased from Beijing Vital River Laboratory Animal Co., LTD. All rats were housed in an SPF animal laboratory (22 &#x000b1; 2 &#x000b0;C, 40&#x02212;70% humidity) with an alternating 12 h light&#x02013;dark cycle. The rats were fed a maintenance diet and had free access to water. All rats were adaptively fed for three days before the experiment and randomly divided into a control group (A) and irradiation group (B). There were 6 rats in group A and B in each study. The control group was not treated before the experiment, and the irradiation group was treated with lead mold to control the irradiated area and received abdominal X-ray irradiation (5 Gy, 2 Gy/min) 24 h before the experiment. The samples collected were processed and then stored at &#x02212;80 &#x000b0;C until analysis.</p><sec id="sec2dot4dot1-pharmaceutics-17-00268"><title>2.4.1. In Vivo Pharmacokinetics Studies</title><p>Valsartan was administered by gavage (10 mg/kg) after forming a homogeneous suspension (2 mg/mL) with 1% CMC-Na by grinding and stirring. Before and after administration (0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 12, and 24 h), the rats in group A (<italic toggle="yes">n</italic> = 6) and group B (<italic toggle="yes">n</italic> = 6) were anesthetized with isoflurane. Blood samples were collected by the orbital blood sampling method, and whole blood was collected by blood collection tubes coated with heparin sodium. Plasma samples were obtained by centrifugation at 16,260&#x000d7; <italic toggle="yes">g</italic> for 10 min.</p></sec><sec id="sec2dot4dot2-pharmaceutics-17-00268"><title>2.4.2. In Vivo Excretion Studies</title><p>For the VAL urinary and fecal excretion assay, six rats in each group, A and B, were randomly assigned to metabolic cages and administered valsartan (10 mg/kg) via gavage. Feces and urine samples were collected within 12 h before administration and at various time points thereafter. The feces and urine were mixed with a 50% methanol&#x02013;water solution at a ratio of 1:4, homogenized, and then centrifuged at 16,260&#x000d7; <italic toggle="yes">g</italic> for 10 min. The resulting supernatant was collected as the analytical samples.</p><p>For the VAL bile secretion assay, six rats in each group, A and B, underwent bile duct cannulation prior to administration. After anesthesia, the abdominal cavity of the rats was opened, followed by separation and ligation of the distal end of the common bile duct. A small opening was made at the front end of the ligation to insert a catheter, which was then ligated and fixed before suturing the abdominal cavity. Bile was collected through a catheter. The rats were maintained under anesthesia with intraperitoneal injection of normal saline and glucose to ensure stable vital signs. Following surgery, valsartan (10 mg/kg) was administered via gavage, and bile samples were collected at different time points post-administration. The collected bile samples were mixed with 50% methanol&#x02013;water (ratio 1:9), centrifuged to obtain the supernatant for analysis.</p></sec><sec id="sec2dot4dot3-pharmaceutics-17-00268"><title>2.4.3. Ex Vivo Inverted Intestinal Sac Absorption Study</title><p>Six rats in groups A and B were anesthetized with isoflurane, followed by the opening of the abdominal cavity to separate a 10 cm segment of the jejunum. The distal end of the jejunal segment was ligated in Krebs&#x02013;Ringer Solution (KRB), and the resulting intestinal sac was turned inside out from the proximal end to form an inverted intestinal sac. Subsequently, 1 mL of KRB buffer at 37 &#x000b0;C was added to the inverted intestinal sac, which was then equilibrated in oxygen-saturated KRB buffer (37 &#x000b0;C) for 5 min. The flipped intestinal sac was transferred to oxygen-saturated KRB buffer (37 &#x000b0;C) containing 10 mM VAL, initiating the timing process. At different time points, 50 &#x003bc;L of solution from the flipped intestinal sac was aspirated and supplemented with an equal volume (50 &#x003bc;L) of blank KRB buffer.</p></sec></sec><sec id="sec2dot5-pharmaceutics-17-00268"><title>2.5. Cell Culture and Treatments</title><p>The Caco-2 cells were obtained from Procell Technology (Wuhan, China). The cells were cultured and passaged under controlled conditions of 37 &#x000b0;C, 5% CO<sub>2</sub>, and 95% relative humidity using DMEM supplemented with 10% fetal bovine serum and 1% penicillin&#x02013;streptomycin. The DMEM was refreshed every alternate day.</p><sec id="sec2dot5dot1-pharmaceutics-17-00268"><title>2.5.1. Cell Counting Kit-8 Assay</title><p>The Caco-2 cells were seeded in 96-well plates at a density of 7000 cells per well. After 48 h of culture, the original medium was removed and replaced with 90 &#x003bc;L of DMEM (without FBS) containing varying concentrations of valsartan (Val, 10 &#x003bc;M), MK571 (10, 50, 100, and 200 &#x003bc;M), or verapamil (Ver, 10, 50, 100, and 200 &#x003bc;M). Following a 6 h incubation period, each well was supplemented with 10 &#x003bc;L of CCK8 reagent and subsequently incubated at 37 &#x000b0;C in the absence of light for an additional 2 h. Subsequently, the absorbance at a wavelength of 405 nm was measured using a microplate reader to determine the cell viability.</p></sec><sec id="sec2dot5dot2-pharmaceutics-17-00268"><title>2.5.2. Cell Uptake Assay</title><p>Caco-2 cells were seeded in 24-well plates at a density of 5 &#x000d7; 10<sup>5</sup> cells per well. After 14 days of culture, the cells in different plates were divided into the control group and irradiation (IR) group. The cells in the IR group received X-ray irradiation (5 Gy, 2 Gy/min) and recovery for 24 h. The wells were washed three times with PBS (phosphate-buffered saline, prewarmed at 37 &#x000b0;C), and then blank medium or medium containing MK571 (Mrp2 inhibitor, 10 &#x003bc;M) or verapamil (P-gp inhibitor, 100 &#x003bc;M) was added to the wells and preincubated at 37 &#x000b0;C for 5 min. Then, the medium containing valsartan (10 &#x003bc;M) or the medium containing valsartan (10 &#x003bc;M) and inhibitor (10 &#x003bc;M MK571 or 100 &#x003bc;M Ver) was then added, and the timing was initiated, maintaining a constant temperature of 37 &#x000b0;C throughout the experiment. At the indicated time points, the culture medium was removed and each well was rinsed thrice with ice-cold phosphate-buffered saline (PBS). Subsequently, 200 &#x003bc;L of 1% Triton X-100 was added to each well for cellular lysis. The protein concentration in the supernatant was determined by bicinchoninic acid assay (BCA) kit, while the concentration of valsartan was quantified by LC-MS/MS.</p></sec></sec><sec id="sec2dot6-pharmaceutics-17-00268"><title>2.6. Real-Time Quantification Polymerase Chain Reaction (RT-qPCR) Studies</title><p>Caco-2 cells, which were cultured to 60% growth density, or SD rats were randomly divided into control group, IR-12 h, IR-24 h, IR-48 h, and IR-72 h irradiation groups (<italic toggle="yes">n</italic> = 4). Except for the control group, all groups received X-ray irradiation at the same dose and using the same method as before. At the indicated time points, the rats were euthanized. The collected jejunum and liver tissues were washed with normal saline and frozen at &#x02212;80 &#x000b0;C. The Caco-2 cells were removed from the medium and washed three times with PBS. A certain amount of RNA extraction reagent (TRIzol) was added to the aforementioned tissue samples or cells, and the tissue or cells were homogenized. After chloroform was added, the lysate was centrifuged, and the clear supernatant was obtained. RNA was precipitated from the supernatant using isopropanol. The precipitate was washed with 80% ethanol&#x02013;water to remove impurities, dried, and then re-dissolved in DEPC water to obtain total RNA. The RNA content was determined by measuring the optical absorbance at 260 nm using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Inc., Waltham, MA, USA). The RNA was reverse transcribed to obtain cDNA templates, which were mixed with the designed primers (Sangon, Inc., Shanghai, China) and TB Green Ex Taq II (Takara, Inc., Kusatsu, Japan) (<xref rid="app1-pharmaceutics-17-00268" ref-type="app">Table S1</xref>) and amplified by real-time fluorescence quantitative PCR (<xref rid="app1-pharmaceutics-17-00268" ref-type="app">Table S2</xref>). &#x003b2;-actin was used as a housekeeping gene, and the relative expression of the target gene was calculated using the 2<sup>&#x02212;&#x00394;&#x00394;Ct</sup> method. The primer sequences are shown in <xref rid="app1-pharmaceutics-17-00268" ref-type="app">Table S3</xref>.</p></sec><sec id="sec2dot7-pharmaceutics-17-00268"><title>2.7. Biochemical Analysis of Oxidative Stress</title><p>The rat jejunal tissue (100 mg) was mixed with normal saline at a ratio of 1:9, followed by chopping on ice and homogenization using a homogenizer. Subsequently, the mixture was centrifuged at 3000 rpm and 4 &#x000b0;C for 15 min. The resulting supernatant was utilized to assess the levels of glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT) in intestinal tissue based on the manufacturer&#x02019;s instructions.</p></sec><sec id="sec2dot8-pharmaceutics-17-00268"><title>2.8. Statistical Analysis</title><p>Quantitative analysis of LC-MS/MS results was performed using Analyst 1.6.3 program. The pharmacokinetic parameters were calculated using the WinNonlin 8.3 program. SPSS Statistic 20.0 software was used for statistical analysis. One-way ANOVA was used for comparison among multiple groups, and <italic toggle="yes">p</italic> &#x0003c; 0.05 was considered statistically significant. GraphPad Prism 8.0.2 software was used for generating figures.</p></sec></sec><sec sec-type="results" id="sec3-pharmaceutics-17-00268"><title>3. Results</title><sec id="sec3dot1-pharmaceutics-17-00268"><title>3.1. Validation of LC-MS/MS Quantitative Method</title><p>As shown in <xref rid="app1-pharmaceutics-17-00268" ref-type="app">Figure S1</xref>, the retention times of valsartan and the internal standard (IS) are 2.11 min and 1.88 min, respectively. The peaks of valsartan and the internal standard are well shaped, while there are no impurity peaks interfering with the retention times of the substances nearby. The baseline response is less than 20% of the valsartan at LLOQ and 5% of the IS, which indicated that endogenous substances in rat plasma do not interfere with the determination of valsartan, and the method has good selectivity and specificity. The results (<xref rid="app1-pharmaceutics-17-00268" ref-type="app">Table S4</xref>) showed that the intra-day and inter-day precision (relative standard deviation, RSD%) of valsartan were between 0.78 and 5.99% and 0.71 and 6.22%, respectively. The accuracy ranged from 100.3 to 104.4%. The intra-day and inter-day precision and accuracy of LLOQ, LQC, MQC, and HQC met the relevant requirements of the M10 guidelines published by the ICH. The calibration curve in rat plasma samples ranged from 2 to 5000 ng/mL. The correlation coefficients of all curves were &#x02265;0.99, indicating that the concentration of valsartan had good linearity in the range of the curve (<xref rid="app1-pharmaceutics-17-00268" ref-type="app">Table S5</xref>).</p><p>As shown in <xref rid="app1-pharmaceutics-17-00268" ref-type="app">Table S6</xref>, the matrix effects of LQC and HQC of valsartan were 100.78% and 97.78%, respectively, and the corresponding RSD were 7.96% and 2.58%, respectively, which were within &#x000b1;15%. The matrix effect of the IS was 103.09%, and the corresponding RSD was 3.24%, which was within &#x000b1;15%. The extraction recovery rates of LQC and HQC of valsartan were 97.41% and 103.01%, respectively, and the corresponding RSD were 2.96% and 2.60%, respectively, which were within &#x000b1;15%. The recovery rate of IS was 99.44%, and the corresponding RSD was 2.90%, which was within &#x000b1;15%. The above results indicate the absence of any co-eluting substance that could impact the ionization of valsartan and the internal standard, while also confirming that the extraction recovery meets quantitative requirements.</p></sec><sec id="sec3dot2-pharmaceutics-17-00268"><title>3.2. Effect of X-Ray Irradiation on the Pharmacokinetics of Valsartan in Rat Plasma</title><p>The LC-MS/MS analysis of plasma samples collected post-drug administration (<xref rid="pharmaceutics-17-00268-f001" ref-type="fig">Figure 1</xref>) revealed that valsartan exhibited rapid absorption, with peak plasma concentration observed at approximately 0.25 h, followed by a subsequent faster elimination rate. Interestingly, compared to the control group, the plasma concentration of valsartan in the IR group exhibited a significant decrease during the absorption&#x02013;distribution phase as well as near its peak (<italic toggle="yes">p</italic> &#x0003c; 0.05). In addition, the plasma concentration of valsartan in the control group increased again from 4 h to 8 h, and the reabsorption of valsartan in the IR group had almost no effect on the plasma concentration. Therefore, the plasma concentration of the IR group was lower than that of the control group during 8&#x02013;12 h (<italic toggle="yes">p</italic> &#x0003c; 0.05). The pharmacokinetic parameters of valsartan (<xref rid="pharmaceutics-17-00268-t001" ref-type="table">Table 1</xref>) showed that the area under the concentration&#x02013;time curve (AUC<sub>0&#x02013;24h</sub>) and maximum plasma concentration (C<sub>max</sub>) of valsartan in the IR group decreased by 37% (<italic toggle="yes">p</italic> &#x0003c; 0.05) and 52% (<italic toggle="yes">p</italic> &#x0003c; 0.05), respectively. The plasma half-life (t<sub>1/2</sub>) of valsartan exhibited an upward trend and was prolonged by 41% (from 3.57 h to 5.03 h); however, the time to peak (T<sub>max</sub>) remained unchanged. These findings suggest that radiation may primarily affect the absorption of valsartan, resulting in a decrease in plasma concentration and overall body exposure.</p></sec><sec id="sec3dot3-pharmaceutics-17-00268"><title>3.3. Effect of X-Ray Irradiation on the Secretion of Bile and Urinary and Fecal Excretion of Valsartan in Rats</title><p>The excretion of valsartan was calculated by the concentration and sample volume (or weight), and the fractional excretion of valsartan and the cumulative excretion fraction of valsartan in each time period were obtained through comparison with the corresponding dose administered to the rat. The results showed that the cumulative fractional bile excretion of valsartan in the IR group decreased significantly (<xref rid="pharmaceutics-17-00268-f002" ref-type="fig">Figure 2</xref>A), reaching only 10.83%, 11.52%, and 12.67% of the dose at 15 h, 18 h, and 24 h, respectively, which were significantly lower than those in the control group (22.89%, 26.24%, and 31.26%, respectively). The fractional excretion in the IR group was lower than that in the control group (<xref rid="pharmaceutics-17-00268-f002" ref-type="fig">Figure 2</xref>B). Indeed, feces were the major route of valsartan excretion in rats, with a cumulative excretion of 83%, but the cumulative fractional excretion of valsartan in feces did not exhibit a statistically significant difference between the IR and control groups (<xref rid="pharmaceutics-17-00268-f002" ref-type="fig">Figure 2</xref>C). Valsartan was excreted in a very small amount in the urine (<xref rid="pharmaceutics-17-00268-f002" ref-type="fig">Figure 2</xref>D), and the fractional excretion of valsartan was lower in the IR group than in the control group, with a significant difference at 4 h and 8 h. These results indicated that excretion and bile secretion were not responsible for the decrease in plasma concentrations of valsartan.</p></sec><sec id="sec3dot4-pharmaceutics-17-00268"><title>3.4. Effect of X-Ray Irradiation on the In Vitro Absorption of Valsartan</title><p>In order to exclude the influence of other factors in vivo, an in vitro inverted intestinal sac assay was designed to explore the role of intestine absorption. The in vitro absorption of the IR group exhibited a significant decrease (<xref rid="pharmaceutics-17-00268-f003" ref-type="fig">Figure 3</xref>), which was observed from 1.25 h onwards. The concentration of valsartan in the intestinal sac at the final time point was measured to be 127 &#x000b1; 32.94 ng/mL in the IR group, demonstrating a significant reduction of 38% compared to that observed in the control group (205.6 &#x000b1; 51.72 ng/mL). These findings strongly suggest that diminished absorption is primarily responsible for the decline in plasma concentration of valsartan.</p></sec><sec id="sec3dot5-pharmaceutics-17-00268"><title>3.5. Effect of X-Ray Irradiation on the Uptake of Valsartan in Caco-2 Cell</title><p>To further explore the effect of intestinal absorption on plasma concentration and the role of efflux transporters (Mrp2, P-gp) in the absorption, Caco-2 cells were used for the drug uptake assay. The cytotoxicity of Val at different concentrations and MK571 (Mrp2 inhibitor MK571 and P-gp inhibitor Ver) was detected by cell counting kit-8 (cck8) assay (<xref rid="pharmaceutics-17-00268-f004" ref-type="fig">Figure 4</xref>A). MK571 (10 &#x003bc;M) and verapamil (100 &#x003bc;M) were selected for subsequent cellular experiments.</p><p>The uptake of valsartan in Caco-2 cells increased over time. MK571 significantly enhanced the cellular uptake of valsartan by Caco-2 cells (<italic toggle="yes">p</italic> &#x0003c; 0.05), while verapamil exhibited limited impact on valsartan uptake (<xref rid="pharmaceutics-17-00268-f004" ref-type="fig">Figure 4</xref>B). Furthermore, there was a significant difference in the concentration of valsartan between the MK571 and verapamil groups (<italic toggle="yes">p</italic> &#x0003c; 0.05). These findings suggest that Mrp2 plays a pivotal role in mediating the efflux of valsartan, whereas P-gp may not be substantially involved in transporting this compound. In another set of uptake experiments (<xref rid="pharmaceutics-17-00268-f004" ref-type="fig">Figure 4</xref>C), the IR group demonstrated a significant reduction in valsartan uptake compared with the control group at 1 h (<italic toggle="yes">p</italic> &#x0003c; 0.05), although there was no significant difference between the IR group and the control group at 2 h. MK571 was capable of reversing the IR-induced decrease in uptake, even causing significantly higher uptake than that of the control group (<italic toggle="yes">p</italic> &#x0003c; 0.05). In both the MK571 group and the IR + MK571 group, IR significantly decreased valsartan uptake at both 1 h and 2 h (<italic toggle="yes">p</italic> &#x0003c; 0.05).</p></sec><sec id="sec3dot6-pharmaceutics-17-00268"><title>3.6. Effect of X-Ray Irradiation on the mRNA Expression of Transporters Related to Valsartan</title><p>Previous experiments have demonstrated that absorption is the major factor in radiation-induced pharmacokinetic alterations of valsartan. As efflux transporters, Mrp2 and P-gp in the intestine can affect the intestinal absorption of valsartan. The results of RT-qPCR are shown in <xref rid="pharmaceutics-17-00268-f005" ref-type="fig">Figure 5</xref>. The expression of Mrp2 and P-gp in the rat intestine increased significantly after radiation (<italic toggle="yes">p</italic> &#x0003c; 0.05), reached the highest level at 12 h after radiation, and then gradually decreased. The expressions of Mrp2 and P-gp in Caco-2 cells were also significantly upregulated after radiation (<italic toggle="yes">p</italic> &#x0003c; 0.05), but the amplitude was much lower than that in rat intestinal tissues. In addition, the liver is also distributed in the abdominal cavity and can also be affected by abdominal irradiation. It is closely related to the secretion and excretion of valsartan into bile, so we detected valsartan-related transporters in the liver. The results were shown in <xref rid="app1-pharmaceutics-17-00268" ref-type="app">Figure S2</xref>. P-gp in the liver maintained the same changes as in intestinal tissue, but Mrp2 and uptake transporter oatp2 in the liver were significantly downregulated after radiation, which indicates that the biological effects of radiation vary from organ to organ.</p></sec><sec id="sec3dot7-pharmaceutics-17-00268"><title>3.7. Detection of Biochemical Indicators of Intestinal Oxidative Stress After Irradiation</title><p>GSH is the most significant non-enzymatic antioxidant substance within the body [<xref rid="B57-pharmaceutics-17-00268" ref-type="bibr">57</xref>], and its level can indirectly indicate the extent of cellular oxidative stress. SOD and CAT are also crucial enzymes for eliminating oxygen free radicals [<xref rid="B58-pharmaceutics-17-00268" ref-type="bibr">58</xref>]. As shown in <xref rid="pharmaceutics-17-00268-f006" ref-type="fig">Figure 6</xref>, compared with the control group, the contents of GSH and the activity of SOD in the jejunal tissue decreased significantly from 12 h to 48 h after IR (<italic toggle="yes">p</italic> &#x0003c; 0.05). Compared with the IR-48 h group, the contents of GSH and the activity of SOD in the IR-72 h group increased but were still lower than those in the control group (<italic toggle="yes">p</italic> &#x0003c; 0.05). In contrast to the control group, CAT activity also declined in a time-dependent manner after IR (<italic toggle="yes">p</italic> &#x0003c; 0.05), reaching the lowest level at 48 h.</p></sec><sec id="sec3dot8-pharmaceutics-17-00268"><title>3.8. The Impact of X-Ray Irradiation on the mRNA Expression of Nrf2 and HO-1</title><p>Nrf2 is a key transcription factor that regulates a variety of antioxidant enzymes or substances, including GSH, SOD, and CAT. HO-1 (heme oxygenase-1) is also an antioxidant enzyme regulated downstream of Nrf2 and plays an important role in scavenging ROS produced by oxidative stress [<xref rid="B59-pharmaceutics-17-00268" ref-type="bibr">59</xref>]. The results of mRNA transcription of Nrf2 as well as HO-1 are shown in <xref rid="pharmaceutics-17-00268-f007" ref-type="fig">Figure 7</xref>. Compared with the control group, the mRNA expression of Nrf2 was significantly upregulated after irradiation (<italic toggle="yes">p</italic> &#x0003c; 0.05) and showed a time-dependent manner in general. The expression of HO-1 was significantly increased at 48 h and 72 h after irradiation (<italic toggle="yes">p</italic> &#x0003c; 0.05), which indirectly proves the regulatory role of Nrf2 upregulation on downstream genes.</p></sec></sec><sec sec-type="discussion" id="sec4-pharmaceutics-17-00268"><title>4. Discussion</title><p>In order to accurately analyze valsartan, this study first established a quantitative analysis method of valsartan by LC-MS/MS and carried out methodological verification. Telmisartan, a structural analog of valsartan, was selected as the internal standard [<xref rid="B60-pharmaceutics-17-00268" ref-type="bibr">60</xref>]. Firstly, the ion pairs of valsartan and telmisartan were determined to be <italic toggle="yes">m/z</italic> 436.1&#x02192;207.1 and <italic toggle="yes">m/z</italic> 515.2&#x02192;276.1 according to the ion responses in MS<sub>1</sub> and MS<sub>3</sub> modes, respectively. The MS parameters and mobile phase composition and ratio were optimized in turn, and the results are described in detail in <xref rid="sec2dot2-pharmaceutics-17-00268" ref-type="sec">Section 2.2</xref>. According to the guidance principles of &#x0201c;M10: Bioanalytical Method Validation and Sample Analysis&#x0201d;, published by the ICH [<xref rid="B56-pharmaceutics-17-00268" ref-type="bibr">56</xref>], the selectivity, accuracy, precision, linearity, extraction recovery, and matrix effect of the established analytical method were validated. All the results met the quantitative requirements. The data of method validation are available in the <xref rid="app1-pharmaceutics-17-00268" ref-type="app">Supplementary Material</xref>.</p><p>X-rays or &#x003b3;-rays, as ionizing radiation, can induce molecular dissociation to directly damage macromolecules such as DNA [<xref rid="B61-pharmaceutics-17-00268" ref-type="bibr">61</xref>], and can also induce the ionization of water molecules to produce reactive oxygen species (ROS) [<xref rid="B62-pharmaceutics-17-00268" ref-type="bibr">62</xref>]. The ROS generated can also cause damage to macromolecules and lipids in cells, leading to oxidative stress and the activation of various inflammatory factors and apoptosis-inducing factors within cells, and thereby resulting in apoptosis [<xref rid="B63-pharmaceutics-17-00268" ref-type="bibr">63</xref>]. Consequently, both X-rays and &#x003b3;-rays are employed in cancer radiotherapy in clinical practice [<xref rid="B64-pharmaceutics-17-00268" ref-type="bibr">64</xref>], and diverse fractionated doses are utilized in accordance with different radiotherapy modalities. The fractionated dose of conventional standard radiotherapy is 1.8&#x02013;2 Gy per fraction [<xref rid="B65-pharmaceutics-17-00268" ref-type="bibr">65</xref>], while high-dose fractionated radiotherapy employs a single dose of more than 2 Gy. Stereotactic body radiation therapy (SBRT) utilizes more than 5 Gy per fraction of radiation dose [<xref rid="B66-pharmaceutics-17-00268" ref-type="bibr">66</xref>]. In order to simulate the clinical radiation dose and achieve a good effect for the RT-PK study, a dose of 5 Gy and a dose rate of 2 Gy/min were selected.</p><p>The in vivo study showed that the pharmacokinetics of valsartan after oral administration was significantly influenced in rats exposed to X-rays in the abdominal region (three finger widths below the xiphoid process) under the cover of a lead mold, as indicated by a 37% reduction in the AUC<sub>0&#x02013;24h</sub> and a 52% reduction in the C<sub>max</sub> of valsartan (<xref rid="pharmaceutics-17-00268-t001" ref-type="table">Table 1</xref>). The occurrence of this phenomenon may be related to reduced absorption, increased metabolism and accelerated excretion. However, valsartan exists in the body in its original form, so metabolic reasons can be ruled out. According to the concentration&#x02013;time curve (<xref rid="pharmaceutics-17-00268-f001" ref-type="fig">Figure 1</xref>) and the calculated pharmacokinetic parameters, this may be related to the decreased intestinal absorption of valsartan after exposure to radiation. However, this inference needs to be verified by further studies.</p><p>The excretion of valsartan in urine and feces and the secretion of bile after radiation were examined. As a highly plasma protein-binding drug [<xref rid="B67-pharmaceutics-17-00268" ref-type="bibr">67</xref>], a small amount of valsartan is excreted in urine. The majority of valsartan (&#x0003e;80%) is absorbed into the liver, secreted into the bile, and ultimately passed into the feces along with the unabsorbed valsartan [<xref rid="B68-pharmaceutics-17-00268" ref-type="bibr">68</xref>]. Our experimental results (<xref rid="pharmaceutics-17-00268-f002" ref-type="fig">Figure 2</xref>) also proved that valsartan is mainly excreted in the feces. The uptake transporters oatps and the efflux transporter Mrp2 in the liver are involved in these processes [<xref rid="B40-pharmaceutics-17-00268" ref-type="bibr">40</xref>]. Bile secretion results showed that the cumulative excretion fraction of valsartan and the excretion of valsartan in each time period in the bile of irradiated rats decreased (<xref rid="pharmaceutics-17-00268-f002" ref-type="fig">Figure 2</xref>A,B), which may be related to the reduction of the total body exposure of valsartan. In addition, our results from the transporter expression study also showed that Mrp2 and oatp1b2 (rat homologue of human OATP1B1/OATP1B3) were downregulated in rat liver (<xref rid="app1-pharmaceutics-17-00268" ref-type="app">Figure S2</xref>), which may also contribute to the reduced bile secretion of valsartan. The opposite trend to the upregulation of intestinal Mrp2 needs attention and further investigation in the future. The absence of a significant change in the fecal excretion of valsartan may be attributed to the low bioavailability of valsartan (23%) [<xref rid="B69-pharmaceutics-17-00268" ref-type="bibr">69</xref>] and the presence of large amounts of unabsorbed valsartan in feces; however, the decrease in the bile secretion of valsartan counteracts the effect of the increased unabsorbed drug. Although the concentration of valsartan in urine significantly decreased from 4 h to 8 h after irradiation, the total amount was too low to be of practical significance. In conclusion, the results of the study on bile secretion and urinary or fecal excretion of valsartan indicate that accelerated excretion is absent in the RT-PK phenomenon of valsartan. Thus, decreased absorption may have contributed to the decrease in AUC of valsartan in the in vivo study.</p><p>To further determine the effect of absorption and the mechanism of the decreased absorption, we designed an ex vivo inverted intestinal sac assay and an uptake assay in Caco-2 cells. Caco-2 is a human clonal colon adenocarcinoma cell line, which is structurally and functionally similar to differentiated small intestinal epithelial cells [<xref rid="B70-pharmaceutics-17-00268" ref-type="bibr">70</xref>]. Differentiated Caco-2 cells have a microvillous structure and express antibodies such as Mrp2 and P-gp [<xref rid="B70-pharmaceutics-17-00268" ref-type="bibr">70</xref>]. Caco-2 was often employed to study the mechanism of drug transport and drug absorption. The results of the inverted intestinal sac assay (<xref rid="pharmaceutics-17-00268-f003" ref-type="fig">Figure 3</xref>) and the cellular uptake results (<xref rid="pharmaceutics-17-00268-f004" ref-type="fig">Figure 4</xref>) confirmed our conjecture that the upregulation of intestinal efflux transporters Mrp2 and P-gp caused by radiation reduced the total amount of drug absorbed into the blood. This hypothesis was supported by our PCR results in the intestine and in Caco-2 cells (<xref rid="pharmaceutics-17-00268-f005" ref-type="fig">Figure 5</xref>).</p><p>However, based on the results of cellular uptake, Mrp2 seemed to play a more significant role in valsartan transport, while the P-gp inhibitor verapamil did not significantly increase the uptake of valsartan by Caco-2 cells (<xref rid="pharmaceutics-17-00268-f004" ref-type="fig">Figure 4</xref>B). We therefore concentrated on intestinal Mrp2 expression as the cause of decreased uptake. Some studies have indicated that oxidative stress within the body can bring about alterations in the expression of metabolic enzymes [<xref rid="B71-pharmaceutics-17-00268" ref-type="bibr">71</xref>,<xref rid="B72-pharmaceutics-17-00268" ref-type="bibr">72</xref>] and transporters, which include the Mrp2 [<xref rid="B73-pharmaceutics-17-00268" ref-type="bibr">73</xref>] and P-gp [<xref rid="B35-pharmaceutics-17-00268" ref-type="bibr">35</xref>]. To explore whether X-rays also induce an increase in Mrp2 in the rat intestine via oxidative stress, we measured the contents of GSH, SOD, and CAT in the intestinal tissue after radiation (<xref rid="pharmaceutics-17-00268-f006" ref-type="fig">Figure 6</xref>), and the results demonstrated that oxidative stress indeed occurred in rats after irradiation.</p><p>Nrf2, a crucial intracellular transcription factor that governs oxidative stress [<xref rid="B74-pharmaceutics-17-00268" ref-type="bibr">74</xref>], is activated in response to oxidative stress [<xref rid="B73-pharmaceutics-17-00268" ref-type="bibr">73</xref>]. Nrf2 is also implicated in the regulation of multiple transporters [<xref rid="B36-pharmaceutics-17-00268" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceutics-17-00268" ref-type="bibr">37</xref>,<xref rid="B73-pharmaceutics-17-00268" ref-type="bibr">73</xref>], among which Mrp2 is included. Knockdown or silencing of the Nrf2 gene leads to the downregulation of Mrp2 expression [<xref rid="B75-pharmaceutics-17-00268" ref-type="bibr">75</xref>]. Nrf2 could be regulated at multiple levels [<xref rid="B76-pharmaceutics-17-00268" ref-type="bibr">76</xref>], encompassing transcriptional regulation [<xref rid="B77-pharmaceutics-17-00268" ref-type="bibr">77</xref>], post-transcriptional regulation, post-translational regulation [<xref rid="B78-pharmaceutics-17-00268" ref-type="bibr">78</xref>], and self-stability regulation. For example, knocking down the upstream Nf-&#x003ba;B of Nrf2 can significantly reduce the expression of Nrf2 [<xref rid="B75-pharmaceutics-17-00268" ref-type="bibr">75</xref>]. Simultaneously, oxidative or covalent modification of cysteine residues Cys273, Cys288, and Cys151 of Keap1 can result in a reduction in Nrf2 ubiquitination, inducing Nrf2 to be released from Keap1 and translocate to the nucleus to exert a transcriptional regulatory role [<xref rid="B79-pharmaceutics-17-00268" ref-type="bibr">79</xref>]. Nrf2 exerts a positive regulatory effect on various antioxidant factors, including NQO1, HO-1, SOD, CAT, and GSH [<xref rid="B80-pharmaceutics-17-00268" ref-type="bibr">80</xref>], while also playing a crucial role in GSH regeneration. Our transcriptional analysis revealed significant upregulation of both Nrf2 and its downstream target HO-1 in the rat intestine following radiation exposure (<xref rid="pharmaceutics-17-00268-f007" ref-type="fig">Figure 7</xref>). The peak upregulation of Nrf2 occurred at 72 h post-radiation, which was consistent with the observed changes in GSH levels as well as SOD and CAT activities (<xref rid="pharmaceutics-17-00268-f006" ref-type="fig">Figure 6</xref>). Simultaneously, the quantity of reactive oxygen species (ROS) rises after radiation exposure, while the expression of Nrf2 gradually escalates, resulting in a gradual reduction in the levels of GSH, SOD, and CAT, but at a declined pace, and a restoration or near-normal level by 72 h post-irradiation. The intestinal expression of Mrp2 mRNA exhibited a similar trend to that of Nrf2, displaying a significant increase following radiation exposure. This finding further supports the regulatory role of Nrf2 in modulating Mrp2 expression through subsequent mechanisms, ultimately leading to reduced absorption of valsartan. The reduction in the peak blood concentration and AUC of valsartan may compromise its antihypertensive efficacy, potentially leading to inadequate blood pressure control and an increased risk of cardiovascular events. Therefore, it is recommended to closely monitor blood pressure fluctuations and promptly adjust the dosage of valsartan in patients with cancer and hypertension undergoing radiotherapy. This will contribute to the sustainability of cancer treatment and avoid the forced discontinuation of cancer drug use due to uncontrolled worsening of hypertension [<xref rid="B21-pharmaceutics-17-00268" ref-type="bibr">21</xref>].</p><p>The biological effects of radiation may vary according to the organ and area exposed. We found that Mrp2 is downregulated in the liver (<xref rid="app1-pharmaceutics-17-00268" ref-type="app">Figure S2</xref>), which may be related to other pathways involved in regulating Mrp2 expression in liver cells [<xref rid="B81-pharmaceutics-17-00268" ref-type="bibr">81</xref>]. The downregulation of hepatic Mrp2 may result in bile stasis and enhance the hepatotoxicity of specific drugs. Radiation can also upregulate P-gp while downregulating oatp2 (<xref rid="app1-pharmaceutics-17-00268" ref-type="app">Figure S2</xref>). Although p-gp was not shown to be involved in the cellular uptake of valsartan in our experiments, it remains unclear whether P-gp played a role in the reduced intestinal absorption of valsartan following radiation exposure. Given its broad substrate specificity, P-gp-mediated RT-PK interactions can occur with a wide range of drugs and induce toxicity or side effects.</p><p>In conclusion, our study has discovered that X-ray irradiation attenuated the intestinal absorption of valsartan, resulting in reduced C<sub>max</sub> and overall exposure of valsartan in vivo in rats. This phenomenon may be attributed to the upregulation of intestinal Nrf2-Mrp2 through radiation-induced oxidative stress (<xref rid="pharmaceutics-17-00268-f008" ref-type="fig">Figure 8</xref>). Further studies are warranted to validate these findings and investigate additional affected transporters, thereby providing a fundamental reference for mitigating potential clinical RT-PK risks in more drugs.</p></sec></body><back><ack><title>Acknowledgments</title><p>We are grateful to all of the coauthors who contributed in any way to this work, as well as to the editors and reviewers for their time in reviewing this manuscript.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-pharmaceutics-17-00268"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/pharmaceutics17020268/s1">https://www.mdpi.com/article/10.3390/pharmaceutics17020268/s1</uri>, Figure S1: Chromatograms of valsartan and telmisartan in rat blank plasma samples (A,B), LLOQ (C,D), and plasma samples from 0.5 h after drug administration (E,F); Figure S2: Relative mRNA expression of Mrp2/&#x003b2;-actin (A), P-gp/&#x003b2;-actin (B), and oatp1b2/&#x003b2;-actin (C) in rat liver after irradiation with 5 Gy of X-rays (Mean &#x000b1; SD, <italic toggle="yes">n</italic> = 4, * indicates the control group compared, * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01, *** <italic toggle="yes">p</italic> &#x0003c; 0.001); Table S1: System of RT-qPCR; Table S2: RT-qPCR amplification system; Table S3: Sequence of primers used for RT-qPCR; Table S4: Intra-day and inter-day precision and accuracy of the method for the determination of valsartan in rat plasma (Mean, <italic toggle="yes">n</italic> = 6); Table S5: Calibration curve and correlation coefficient of valsartan quantification in rat plasma by LC-MS/MS; Table S6: Matrix effects and extraction recovery of valsartan and telmisartan (IS) in rat plasma (Mean &#x000b1; SD, <italic toggle="yes">n</italic> = 6).</p><supplementary-material id="pharmaceutics-17-00268-s001" position="float" content-type="local-data"><media xlink:href="pharmaceutics-17-00268-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, A.Z.; methodology, Y.T.; software, B.L.; validation, Y.T.; formal analysis, Y.T. and B.L.; investigation, Y.T., J.M. and J.Z.; resources, J.M., J.Z., Y.L. and S.D.; data curation, Y.T. and Y.L.; writing&#x02014;original draft, Y.T.; writing&#x02014;review and editing, H.F.; supervision, A.Z., S.D. and H.F.; funding acquisition, S.D. and H.F. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The animal use protocol in this study was approved by the Experimental Animal Ethics Committee, Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Tianjin, China (approval No. IRM-DWLL-2023005).</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are available on request from the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></notes><glossary><title>Abbreviations</title><array><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">AUC</td><td align="left" valign="top" rowspan="1" colspan="1">area under the drug&#x02013;time curve</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ARBs</td><td align="left" valign="top" rowspan="1" colspan="1">angiotensin II receptor blockers</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BCA</td><td align="left" valign="top" rowspan="1" colspan="1">bicinchoninic acid assay</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CAT</td><td align="left" valign="top" rowspan="1" colspan="1">catalase</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">cck8</td><td align="left" valign="top" rowspan="1" colspan="1">cell counting kit-8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CE</td><td align="left" valign="top" rowspan="1" colspan="1">collision energy</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CL</td><td align="left" valign="top" rowspan="1" colspan="1">clearance rate</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">C<sub>max</sub></td><td align="left" valign="top" rowspan="1" colspan="1">maximum plasma concentration</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CMC-Na</td><td align="left" valign="top" rowspan="1" colspan="1">sodium carboxymethylcellulose</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CXP</td><td align="left" valign="top" rowspan="1" colspan="1">collision cell exit potential</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DMEM</td><td align="left" valign="top" rowspan="1" colspan="1">Dulbecco&#x02019;s modified eagle medium</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DP</td><td align="left" valign="top" rowspan="1" colspan="1">declustering potential</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">EP</td><td align="left" valign="top" rowspan="1" colspan="1">entrance potential</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ESI</td><td align="left" valign="top" rowspan="1" colspan="1">electrospray ionization</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FBS</td><td align="left" valign="top" rowspan="1" colspan="1">fetal bovine serum</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GSH</td><td align="left" valign="top" rowspan="1" colspan="1">glutathione</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HO-1</td><td align="left" valign="top" rowspan="1" colspan="1">heme oxygenase-1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HQC</td><td align="left" valign="top" rowspan="1" colspan="1">high quality control</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ICH</td><td align="left" valign="top" rowspan="1" colspan="1">International Coordinating Committee for Technical Requirements for Medicinal Products for Human Use</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IR</td><td align="left" valign="top" rowspan="1" colspan="1">irradiation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IS</td><td align="left" valign="top" rowspan="1" colspan="1">internal standard</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KRB</td><td align="left" valign="top" rowspan="1" colspan="1">Krebs&#x02013;Ringer Solution</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LC-MS/MS</td><td align="left" valign="top" rowspan="1" colspan="1">liquid chromatography tandem mass spectrometry</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LLOQ</td><td align="left" valign="top" rowspan="1" colspan="1">lower limit of quantitation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LQC</td><td align="left" valign="top" rowspan="1" colspan="1">lower quality control</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MQC</td><td align="left" valign="top" rowspan="1" colspan="1">medium quality control</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mrp2</td><td align="left" valign="top" rowspan="1" colspan="1">multidrug resistance-associated protein 2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">m/z</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">mass-to-charge ratio</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nf-&#x003ba;B</td><td align="left" valign="top" rowspan="1" colspan="1">nuclear factor kappa-B</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NQO1</td><td align="left" valign="top" rowspan="1" colspan="1">NADH quinone oxidoreductase 1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nrf2</td><td align="left" valign="top" rowspan="1" colspan="1">nuclear factor erythroid 2-related factor 2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">oatp1b2</td><td align="left" valign="top" rowspan="1" colspan="1">organic anion-transporting polypeptide 1b2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">OATP1B1/3</td><td align="left" valign="top" rowspan="1" colspan="1">organic anion-transporting polypeptide 1B1/3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PBS</td><td align="left" valign="top" rowspan="1" colspan="1">phosphate-buffered saline</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-gp</td><td align="left" valign="top" rowspan="1" colspan="1">P-glycoprotein</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ROS</td><td align="left" valign="top" rowspan="1" colspan="1">reactive oxygen species</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RSD</td><td align="left" valign="top" rowspan="1" colspan="1">relative standard deviation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RT-PK</td><td align="left" valign="top" rowspan="1" colspan="1">radiation pharmacokinetics</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RT-qPCR</td><td align="left" valign="top" rowspan="1" colspan="1">real-time quantification polymerase chain reaction</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SBRT</td><td align="left" valign="top" rowspan="1" colspan="1">stereotactic body radiation therapy</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SOD</td><td align="left" valign="top" rowspan="1" colspan="1">superoxide dismutase</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">t<sub>1/2</sub></td><td align="left" valign="top" rowspan="1" colspan="1">half-life</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">T<sub>max</sub></td><td align="left" valign="top" rowspan="1" colspan="1">peak time</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">VAL</td><td align="left" valign="top" rowspan="1" colspan="1">valsartan</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">V<sub>d</sub></td><td align="left" valign="top" rowspan="1" colspan="1">apparent volume of distribution</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ver</td><td align="left" valign="top" rowspan="1" colspan="1">verapamil</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-pharmaceutics-17-00268"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qiao</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Xin</surname><given-names>Y.</given-names></name>
<name><surname>Nian</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Duan</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
</person-group><article-title>Effect of X-ray irradiation on pharmacokinetics of irinotecan hydrochloride and expression of CES1 and CYP3A1 in rats</article-title><source>Fundam. Clin. Pharmacol.</source><year>2019</year><volume>33</volume><fpage>558</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1111/fcp.12456</pub-id><pub-id pub-id-type="pmid">30811654</pub-id>
</element-citation></ref><ref id="B2-pharmaceutics-17-00268"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Nagata</surname><given-names>K.</given-names></name>
<name><surname>Masunaga</surname><given-names>S.</given-names></name>
<name><surname>Suzuki</surname><given-names>M.</given-names></name>
<name><surname>Kashino</surname><given-names>G.</given-names></name>
<name><surname>Kinashi</surname><given-names>Y.</given-names></name>
<name><surname>Tanaka</surname><given-names>H.</given-names></name>
<name><surname>Sakurai</surname><given-names>Y.</given-names></name>
<name><surname>Maruhashi</surname><given-names>A.</given-names></name>
<name><surname>Ono</surname><given-names>K.</given-names></name>
</person-group><article-title>Gamma-ray irradiation enhanced boron-10 compound accumulation in murine tumors</article-title><source>J. Radiat. Res.</source><year>2009</year><volume>50</volume><fpage>553</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1269/jrr.09071</pub-id><pub-id pub-id-type="pmid">19801890</pub-id>
</element-citation></ref><ref id="B3-pharmaceutics-17-00268"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>J.H.</given-names></name>
<name><surname>Tsai</surname><given-names>T.H.</given-names></name>
<name><surname>Chen</surname><given-names>Y.J.</given-names></name>
<name><surname>Wang</surname><given-names>L.Y.</given-names></name>
<name><surname>Liu</surname><given-names>H.Y.</given-names></name>
<name><surname>Hsieh</surname><given-names>C.H.</given-names></name>
</person-group><article-title>Local Irradiation Modulates the Pharmacokinetics of Metabolites in 5-Fluorouracil-Radiotherapy-Pharmacokinetics Phenomenon</article-title><source>Front. Pharmacol.</source><year>2020</year><volume>11</volume><elocation-id>141</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2020.00141</pub-id><pub-id pub-id-type="pmid">32174836</pub-id>
</element-citation></ref><ref id="B4-pharmaceutics-17-00268"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dong</surname><given-names>S.Q.</given-names></name>
<name><surname>Yang</surname><given-names>F.</given-names></name>
<name><surname>Zhang</surname><given-names>D.X.</given-names></name>
<name><surname>Wang</surname><given-names>L.M.</given-names></name>
<name><surname>Liu</surname><given-names>J.F.</given-names></name>
<name><surname>Zhang</surname><given-names>A.J.</given-names></name>
<name><surname>Fan</surname><given-names>H.R.</given-names></name>
</person-group><article-title>Effect of X-ray radiation on the pharmacokinetics of apatinib in vivo in rats</article-title><source>Front. Pharmacol.</source><year>2022</year><volume>13</volume><elocation-id>943812</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2022.943812</pub-id><pub-id pub-id-type="pmid">36188594</pub-id>
</element-citation></ref><ref id="B5-pharmaceutics-17-00268"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dong</surname><given-names>S.</given-names></name>
<name><surname>Yang</surname><given-names>F.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Teng</surname><given-names>Y.</given-names></name>
<name><surname>Tang</surname><given-names>W.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Fan</surname><given-names>H.</given-names></name>
</person-group><article-title>Effect of X-ray irradiation on renal excretion of bestatin through down-regulating organic anion transporters via the vitamin D receptor in rats</article-title><source>Chem. Biol. Interact.</source><year>2024</year><volume>399</volume><elocation-id>111123</elocation-id><pub-id pub-id-type="doi">10.1016/j.cbi.2024.111123</pub-id><pub-id pub-id-type="pmid">38964638</pub-id>
</element-citation></ref><ref id="B6-pharmaceutics-17-00268"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y.J.</given-names></name>
<name><surname>Tsai</surname><given-names>T.H.</given-names></name>
<name><surname>Wang</surname><given-names>L.Y.</given-names></name>
<name><surname>Hsieh</surname><given-names>C.H.</given-names></name>
</person-group><article-title>Local Radiotherapy Affects Drug Pharmacokinetics-Exploration of a Neglected but Significant Uncertainty of Cancer Therapy</article-title><source>Technol. Cancer Res. Treat.</source><year>2017</year><volume>16</volume><fpage>705</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1177/1533034617737011</pub-id><pub-id pub-id-type="pmid">29332468</pub-id>
</element-citation></ref><ref id="B7-pharmaceutics-17-00268"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Ma</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>M.</given-names></name>
<name><surname>Fan</surname><given-names>J.</given-names></name>
<name><surname>Hu</surname><given-names>S.</given-names></name>
</person-group><article-title>Summary of the 2022 Report on Cardiovascular Health and Diseases in China</article-title><source>Chin. Med. J.</source><year>2023</year><volume>136</volume><fpage>2899</fpage><lpage>2908</lpage><pub-id pub-id-type="doi">10.1097/CM9.0000000000002927</pub-id><pub-id pub-id-type="pmid">38018129</pub-id>
</element-citation></ref><ref id="B8-pharmaceutics-17-00268"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qiu</surname><given-names>H.</given-names></name>
<name><surname>Cao</surname><given-names>S.</given-names></name>
<name><surname>Xu</surname><given-names>R.</given-names></name>
</person-group><article-title>Cancer incidence, mortality, and burden in China: A time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020</article-title><source>Cancer Commun.</source><year>2021</year><volume>41</volume><fpage>1037</fpage><lpage>1048</lpage><pub-id pub-id-type="doi">10.1002/cac2.12197</pub-id></element-citation></ref><ref id="B9-pharmaceutics-17-00268"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van Dorst</surname><given-names>D.C.H.</given-names></name>
<name><surname>Dobbin</surname><given-names>S.J.H.</given-names></name>
<name><surname>Neves</surname><given-names>K.B.</given-names></name>
<name><surname>Herrmann</surname><given-names>J.</given-names></name>
<name><surname>Herrmann</surname><given-names>S.M.</given-names></name>
<name><surname>Versmissen</surname><given-names>J.</given-names></name>
<name><surname>Mathijssen</surname><given-names>R.H.J.</given-names></name>
<name><surname>Danser</surname><given-names>A.H.J.</given-names></name>
<name><surname>Lang</surname><given-names>N.N.</given-names></name>
</person-group><article-title>Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients</article-title><source>Circ. Res.</source><year>2021</year><volume>128</volume><fpage>1040</fpage><lpage>1061</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.121.318051</pub-id><pub-id pub-id-type="pmid">33793337</pub-id>
</element-citation></ref><ref id="B10-pharmaceutics-17-00268"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Souza</surname><given-names>V.B.</given-names></name>
<name><surname>Silva</surname><given-names>E.N.</given-names></name>
<name><surname>Ribeiro</surname><given-names>M.L.</given-names></name>
<name><surname>Martins Wde</surname><given-names>A.</given-names></name>
</person-group><article-title>Hypertension in patients with cancer</article-title><source>Arq. Bras. Cardiol.</source><year>2015</year><volume>104</volume><fpage>246</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.5935/abc.20150011</pub-id><pub-id pub-id-type="pmid">25742420</pub-id>
</element-citation></ref><ref id="B11-pharmaceutics-17-00268"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Du</surname><given-names>Y.X.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Ji</surname><given-names>S.W.</given-names></name>
<name><surname>Niu</surname><given-names>N.</given-names></name>
</person-group><article-title>Hypertension toxicity of VEGFR-TKIs in cancer treatment: Incidence, mechanisms, and management strategies</article-title><source>Arch. Toxicol.</source><year>2024</year><volume>99</volume><fpage>67</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1007/s00204-024-03874-4</pub-id><pub-id pub-id-type="pmid">39347999</pub-id>
</element-citation></ref><ref id="B12-pharmaceutics-17-00268"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koene</surname><given-names>R.J.</given-names></name>
<name><surname>Prizment</surname><given-names>A.E.</given-names></name>
<name><surname>Blaes</surname><given-names>A.</given-names></name>
<name><surname>Konety</surname><given-names>S.H.</given-names></name>
</person-group><article-title>Shared Risk Factors in Cardiovascular Disease and Cancer</article-title><source>Circulation</source><year>2016</year><volume>133</volume><fpage>1104</fpage><lpage>1114</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.115.020406</pub-id><pub-id pub-id-type="pmid">26976915</pub-id>
</element-citation></ref><ref id="B13-pharmaceutics-17-00268"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wolin</surname><given-names>K.Y.</given-names></name>
<name><surname>Carson</surname><given-names>K.</given-names></name>
<name><surname>Colditz</surname><given-names>G.A.</given-names></name>
</person-group><article-title>Obesity and cancer</article-title><source>Oncologist</source><year>2010</year><volume>15</volume><fpage>556</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2009-0285</pub-id><pub-id pub-id-type="pmid">20507889</pub-id>
</element-citation></ref><ref id="B14-pharmaceutics-17-00268"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kong</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>N.</given-names></name>
<name><surname>Yang</surname><given-names>X.C.</given-names></name>
<name><surname>Nie</surname><given-names>X.L.</given-names></name>
<name><surname>Tian</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>D.X.</given-names></name>
</person-group><article-title>Nonselective Compared with Selective &#x003b1;-Blockade Is Associated With Less Intraoperative Hypertension in Patients with Pheochromocytomas and Paragangliomas: A Retrospective Cohort Study with Propensity Score Matching</article-title><source>Anesth. Analg.</source><year>2021</year><volume>132</volume><fpage>140</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1213/ANE.0000000000005070</pub-id><pub-id pub-id-type="pmid">32675634</pub-id>
</element-citation></ref><ref id="B15-pharmaceutics-17-00268"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Katsi</surname><given-names>V.</given-names></name>
<name><surname>Magkas</surname><given-names>N.</given-names></name>
<name><surname>Georgiopoulos</surname><given-names>G.</given-names></name>
<name><surname>Athanasiadi</surname><given-names>E.</given-names></name>
<name><surname>Virdis</surname><given-names>A.</given-names></name>
<name><surname>Masi</surname><given-names>S.</given-names></name>
<name><surname>Kliridis</surname><given-names>P.</given-names></name>
<name><surname>Hatziyanni</surname><given-names>A.</given-names></name>
<name><surname>Tsioufis</surname><given-names>C.</given-names></name>
<name><surname>Tousoulis</surname><given-names>D.</given-names></name>
</person-group><article-title>Arterial hypertension in patients under antineoplastic therapy: A systematic review</article-title><source>J. Hypertens.</source><year>2019</year><volume>37</volume><fpage>884</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1097/HJH.0000000000002006</pub-id><pub-id pub-id-type="pmid">30624368</pub-id>
</element-citation></ref><ref id="B16-pharmaceutics-17-00268"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suter</surname><given-names>T.M.</given-names></name>
<name><surname>Ewer</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Cancer drugs and the heart: Importance and management</article-title><source>Eur. Heart J.</source><year>2013</year><volume>34</volume><fpage>1102</fpage><lpage>1111</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehs181</pub-id><pub-id pub-id-type="pmid">22789916</pub-id>
</element-citation></ref><ref id="B17-pharmaceutics-17-00268"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>S.</given-names></name>
<name><surname>Chen</surname><given-names>J.J.</given-names></name>
<name><surname>Kudelka</surname><given-names>A.</given-names></name>
<name><surname>Lu</surname><given-names>J.</given-names></name>
<name><surname>Zhu</surname><given-names>X.</given-names></name>
</person-group><article-title>Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and meta-analysis</article-title><source>Lancet Oncol.</source><year>2008</year><volume>9</volume><fpage>117</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(08)70003-2</pub-id><pub-id pub-id-type="pmid">18221915</pub-id>
</element-citation></ref><ref id="B18-pharmaceutics-17-00268"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Coleman</surname><given-names>R.L.</given-names></name>
<name><surname>Brady</surname><given-names>M.F.</given-names></name>
<name><surname>Herzog</surname><given-names>T.J.</given-names></name>
<name><surname>Sabbatini</surname><given-names>P.</given-names></name>
<name><surname>Armstrong</surname><given-names>D.K.</given-names></name>
<name><surname>Walker</surname><given-names>J.L.</given-names></name>
<name><surname>Kim</surname><given-names>B.G.</given-names></name>
<name><surname>Fujiwara</surname><given-names>K.</given-names></name>
<name><surname>Tewari</surname><given-names>K.S.</given-names></name>
<name><surname>O&#x02019;Malley</surname><given-names>D.M.</given-names></name>
<etal/>
</person-group><article-title>Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): A multicentre, open-label, randomised, phase 3 trial</article-title><source>Lancet Oncol.</source><year>2017</year><volume>18</volume><fpage>779</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(17)30279-6</pub-id><pub-id pub-id-type="pmid">28438473</pub-id>
</element-citation></ref><ref id="B19-pharmaceutics-17-00268"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Perren</surname><given-names>T.J.</given-names></name>
<name><surname>Swart</surname><given-names>A.M.</given-names></name>
<name><surname>Pfisterer</surname><given-names>J.</given-names></name>
<name><surname>Ledermann</surname><given-names>J.A.</given-names></name>
<name><surname>Pujade-Lauraine</surname><given-names>E.</given-names></name>
<name><surname>Kristensen</surname><given-names>G.</given-names></name>
<name><surname>Carey</surname><given-names>M.S.</given-names></name>
<name><surname>Beale</surname><given-names>P.</given-names></name>
<name><surname>Cervantes</surname><given-names>A.</given-names></name>
<name><surname>Kurzeder</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>A phase 3 trial of bevacizumab in ovarian cancer</article-title><source>N. Engl. J. Med.</source><year>2011</year><volume>365</volume><fpage>2484</fpage><lpage>2496</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1103799</pub-id><pub-id pub-id-type="pmid">22204725</pub-id>
</element-citation></ref><ref id="B20-pharmaceutics-17-00268"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oza</surname><given-names>A.M.</given-names></name>
<name><surname>Selle</surname><given-names>F.</given-names></name>
<name><surname>Davidenko</surname><given-names>I.</given-names></name>
<name><surname>Korach</surname><given-names>J.</given-names></name>
<name><surname>Mendiola</surname><given-names>C.</given-names></name>
<name><surname>Pautier</surname><given-names>P.</given-names></name>
<name><surname>Chmielowska</surname><given-names>E.</given-names></name>
<name><surname>Bamias</surname><given-names>A.</given-names></name>
<name><surname>DeCensi</surname><given-names>A.</given-names></name>
<name><surname>Zvirbule</surname><given-names>Z.</given-names></name>
<etal/>
</person-group><article-title>Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study</article-title><source>Int. J. Gynecol. Cancer</source><year>2017</year><volume>27</volume><fpage>50</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1097/IGC.0000000000000836</pub-id><pub-id pub-id-type="pmid">27749456</pub-id>
</element-citation></ref><ref id="B21-pharmaceutics-17-00268"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alexandre</surname><given-names>J.</given-names></name>
<name><surname>Cautela</surname><given-names>J.</given-names></name>
<name><surname>Ederhy</surname><given-names>S.</given-names></name>
<name><surname>Damaj</surname><given-names>G.L.</given-names></name>
<name><surname>Salem</surname><given-names>J.E.</given-names></name>
<name><surname>Barlesi</surname><given-names>F.</given-names></name>
<name><surname>Farnault</surname><given-names>L.</given-names></name>
<name><surname>Charbonnier</surname><given-names>A.</given-names></name>
<name><surname>Mirabel</surname><given-names>M.</given-names></name>
<name><surname>Champiat</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines</article-title><source>J. Am. Heart Assoc.</source><year>2020</year><volume>9</volume><fpage>e018403</fpage><pub-id pub-id-type="doi">10.1161/JAHA.120.018403</pub-id><pub-id pub-id-type="pmid">32893704</pub-id>
</element-citation></ref><ref id="B22-pharmaceutics-17-00268"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zamorano</surname><given-names>J.L.</given-names></name>
<name><surname>Lancellotti</surname><given-names>P.</given-names></name>
<name><surname>Rodriguez Mu&#x000f1;oz</surname><given-names>D.</given-names></name>
<name><surname>Aboyans</surname><given-names>V.</given-names></name>
<name><surname>Asteggiano</surname><given-names>R.</given-names></name>
<name><surname>Galderisi</surname><given-names>M.</given-names></name>
<name><surname>Habib</surname><given-names>G.</given-names></name>
<name><surname>Lenihan</surname><given-names>D.J.</given-names></name>
<name><surname>Lip</surname><given-names>G.Y.H.</given-names></name>
<name><surname>Lyon</surname><given-names>A.R.</given-names></name>
<etal/>
</person-group><article-title>2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)</article-title><source>Eur. Heart J.</source><year>2016</year><volume>37</volume><fpage>2768</fpage><lpage>2801</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehw211</pub-id><pub-id pub-id-type="pmid">27567406</pub-id>
</element-citation></ref><ref id="B23-pharmaceutics-17-00268"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Petrelli</surname><given-names>F.</given-names></name>
<name><surname>Ghidini</surname><given-names>A.</given-names></name>
<name><surname>Cabiddu</surname><given-names>M.</given-names></name>
<name><surname>Perego</surname><given-names>G.</given-names></name>
<name><surname>Lonati</surname><given-names>V.</given-names></name>
<name><surname>Ghidini</surname><given-names>M.</given-names></name>
<name><surname>Oggionni</surname><given-names>E.</given-names></name>
<name><surname>Galli</surname><given-names>E.</given-names></name>
<name><surname>Moleri</surname><given-names>G.</given-names></name>
<name><surname>Barni</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Effects of hypertension on cancer survival: A meta-analysis</article-title><source>Eur. J. Clin. Investig.</source><year>2021</year><volume>51</volume><fpage>e13493</fpage><pub-id pub-id-type="doi">10.1111/eci.13493</pub-id><pub-id pub-id-type="pmid">33470426</pub-id>
</element-citation></ref><ref id="B24-pharmaceutics-17-00268"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ettehad</surname><given-names>D.</given-names></name>
<name><surname>Emdin</surname><given-names>C.A.</given-names></name>
<name><surname>Kiran</surname><given-names>A.</given-names></name>
<name><surname>Anderson</surname><given-names>S.G.</given-names></name>
<name><surname>Callender</surname><given-names>T.</given-names></name>
<name><surname>Emberson</surname><given-names>J.</given-names></name>
<name><surname>Chalmers</surname><given-names>J.</given-names></name>
<name><surname>Rodgers</surname><given-names>A.</given-names></name>
<name><surname>Rahimi</surname><given-names>K.</given-names></name>
</person-group><article-title>Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis</article-title><source>Lancet</source><year>2016</year><volume>387</volume><fpage>957</fpage><lpage>967</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)01225-8</pub-id><pub-id pub-id-type="pmid">26724178</pub-id>
</element-citation></ref><ref id="B25-pharmaceutics-17-00268"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>P.C.</given-names></name>
<name><surname>Huang</surname><given-names>R.Y.</given-names></name>
<name><surname>Yang</surname><given-names>Y.C.</given-names></name>
<name><surname>Hsieh</surname><given-names>K.P.</given-names></name>
<name><surname>Yang</surname><given-names>Y.H.</given-names></name>
</person-group><article-title>Prognostic impact of angiotensin-converting enzyme inhibitors and angiotensin receptors blockers in esophageal or gastric cancer patients with hypertension&#x02014;A real-world study</article-title><source>BMC Cancer</source><year>2022</year><volume>22</volume><elocation-id>430</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-022-09513-4</pub-id><pub-id pub-id-type="pmid">35443635</pub-id>
</element-citation></ref><ref id="B26-pharmaceutics-17-00268"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Novo</surname><given-names>S.</given-names></name>
<name><surname>Lunetta</surname><given-names>M.</given-names></name>
<name><surname>Evola</surname><given-names>S.</given-names></name>
<name><surname>Novo</surname><given-names>G.</given-names></name>
</person-group><article-title>Role of ARBs in the blood hypertension therapy and prevention of cardiovascular events</article-title><source>Curr. Drug Targets</source><year>2009</year><volume>10</volume><fpage>20</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.2174/138945009787122897</pub-id><pub-id pub-id-type="pmid">19149532</pub-id>
</element-citation></ref><ref id="B27-pharmaceutics-17-00268"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gomes</surname><given-names>T.</given-names></name>
<name><surname>Song</surname><given-names>Y.</given-names></name>
<name><surname>Brede</surname><given-names>D.A.</given-names></name>
<name><surname>Xie</surname><given-names>L.</given-names></name>
<name><surname>Gutzkow</surname><given-names>K.B.</given-names></name>
<name><surname>Salbu</surname><given-names>B.</given-names></name>
<name><surname>Tollefsen</surname><given-names>K.E.</given-names></name>
</person-group><article-title>Gamma radiation induces dose-dependent oxidative stress and transcriptional alterations in the freshwater crustacean Daphnia magna</article-title><source>Sci. Total Environ.</source><year>2018</year><volume>628&#x02013;629</volume><fpage>206</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1016/j.scitotenv.2018.02.039</pub-id></element-citation></ref><ref id="B28-pharmaceutics-17-00268"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Niu</surname><given-names>T.</given-names></name>
<name><surname>Zhi</surname><given-names>Y.</given-names></name>
<name><surname>Wei</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>W.</given-names></name>
<name><surname>Ju</surname><given-names>X.</given-names></name>
<name><surname>Pi</surname><given-names>W.</given-names></name>
<name><surname>Fu</surname><given-names>Z.</given-names></name>
<name><surname>Tong</surname><given-names>H.</given-names></name>
<name><surname>Hu</surname><given-names>H.</given-names></name>
<name><surname>Dong</surname><given-names>J.</given-names></name>
</person-group><article-title>Sirtuin 3 controls cardiac energetics and protects against oxidative stress in electromagnetic radiation-induced cardiomyopathy</article-title><source>Free Radic. Biol. Med.</source><year>2023</year><volume>205</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2023.05.031</pub-id><pub-id pub-id-type="pmid">37268048</pub-id>
</element-citation></ref><ref id="B29-pharmaceutics-17-00268"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kita</surname><given-names>K.</given-names></name>
<name><surname>Sugita</surname><given-names>K.</given-names></name>
<name><surname>Sato</surname><given-names>C.</given-names></name>
<name><surname>Sugaya</surname><given-names>S.</given-names></name>
<name><surname>Sato</surname><given-names>T.</given-names></name>
<name><surname>Kaneda</surname><given-names>A.</given-names></name>
</person-group><article-title>Extracellular Release of Annexin A2 is Enhanced upon Oxidative Stress Response via the p38 MAPK Pathway after Low-Dose X-Ray Irradiation</article-title><source>Radiat. Res.</source><year>2016</year><volume>186</volume><fpage>79</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1667/RR14277.1</pub-id><pub-id pub-id-type="pmid">27356027</pub-id>
</element-citation></ref><ref id="B30-pharmaceutics-17-00268"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Castellv&#x000ed;</surname><given-names>A.</given-names></name>
<name><surname>Crespo</surname><given-names>I.</given-names></name>
<name><surname>Crosas</surname><given-names>E.</given-names></name>
<name><surname>C&#x000e1;mara-Artigas</surname><given-names>A.</given-names></name>
<name><surname>Gavira</surname><given-names>J.A.</given-names></name>
<name><surname>Aranda</surname><given-names>M.A.G.</given-names></name>
<name><surname>Par&#x000e9;s</surname><given-names>X.</given-names></name>
<name><surname>Farr&#x000e9;s</surname><given-names>J.</given-names></name>
<name><surname>Juanhuix</surname><given-names>J.</given-names></name>
</person-group><article-title>Efficacy of aldose reductase inhibitors is affected by oxidative stress induced under X-ray irradiation</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><elocation-id>3177</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-39722-0</pub-id><pub-id pub-id-type="pmid">30816220</pub-id>
</element-citation></ref><ref id="B31-pharmaceutics-17-00268"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>B.Y.</given-names></name>
<name><surname>Tang</surname><given-names>X.D.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>H.B.</given-names></name>
<name><surname>Chen</surname><given-names>W.S.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
</person-group><article-title>Rifampicin induces clathrin-dependent endocytosis and ubiquitin-proteasome degradation of MRP2 via oxidative stress-activated PKC-ERK/JNK/p38 and PI3K signaling pathways in HepG2 cells</article-title><source>Acta Pharmacol. Sin.</source><year>2020</year><volume>41</volume><fpage>56</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1038/s41401-019-0266-0</pub-id><pub-id pub-id-type="pmid">31316180</pub-id>
</element-citation></ref><ref id="B32-pharmaceutics-17-00268"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hoshi</surname><given-names>Y.</given-names></name>
<name><surname>Uchida</surname><given-names>Y.</given-names></name>
<name><surname>Tachikawa</surname><given-names>M.</given-names></name>
<name><surname>Ohtsuki</surname><given-names>S.</given-names></name>
<name><surname>Couraud</surname><given-names>P.O.</given-names></name>
<name><surname>Suzuki</surname><given-names>T.</given-names></name>
<name><surname>Terasaki</surname><given-names>T.</given-names></name>
</person-group><article-title>Oxidative stress-induced activation of Abl and Src kinases rapidly induces P-glycoprotein internalization via phosphorylation of caveolin-1 on tyrosine-14, decreasing cortisol efflux at the blood-brain barrier</article-title><source>J. Cereb. Blood Flow Metab.</source><year>2020</year><volume>40</volume><fpage>420</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1177/0271678X18822801</pub-id><pub-id pub-id-type="pmid">30621530</pub-id>
</element-citation></ref><ref id="B33-pharmaceutics-17-00268"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tian</surname><given-names>J.</given-names></name>
<name><surname>Hu</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>G.</given-names></name>
<name><surname>Yin</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>M.</given-names></name>
<name><surname>Miao</surname><given-names>P.</given-names></name>
<name><surname>Bai</surname><given-names>P.</given-names></name>
<name><surname>Yin</surname><given-names>J.</given-names></name>
</person-group><article-title>Altered Gene expression of ABC transporters, nuclear receptors and oxidative stress signaling in zebrafish embryos exposed to CdTe quantum dots</article-title><source>Environ. Pollut.</source><year>2019</year><volume>244</volume><fpage>588</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1016/j.envpol.2018.10.092</pub-id><pub-id pub-id-type="pmid">30384064</pub-id>
</element-citation></ref><ref id="B34-pharmaceutics-17-00268"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ma</surname><given-names>Q.</given-names></name>
</person-group><article-title>Role of nrf2 in oxidative stress and toxicity</article-title><source>Annu. Rev. Pharmacol. Toxicol.</source><year>2013</year><volume>53</volume><fpage>401</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1146/annurev-pharmtox-011112-140320</pub-id><pub-id pub-id-type="pmid">23294312</pub-id>
</element-citation></ref><ref id="B35-pharmaceutics-17-00268"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shchulkin</surname><given-names>A.V.</given-names></name>
<name><surname>Abalenikhina</surname><given-names>Y.V.</given-names></name>
<name><surname>Kosmachevskaya</surname><given-names>O.V.</given-names></name>
<name><surname>Topunov</surname><given-names>A.F.</given-names></name>
<name><surname>Yakusheva</surname><given-names>E.N.</given-names></name>
</person-group><article-title>Regulation of P-Glycoprotein during Oxidative Stress</article-title><source>Antioxidants</source><year>2024</year><volume>13</volume><elocation-id>215</elocation-id><pub-id pub-id-type="doi">10.3390/antiox13020215</pub-id><pub-id pub-id-type="pmid">38397813</pub-id>
</element-citation></ref><ref id="B36-pharmaceutics-17-00268"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lou</surname><given-names>Y.</given-names></name>
<name><surname>Guo</surname><given-names>Z.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>G.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Qi</surname><given-names>X.</given-names></name>
<name><surname>Lu</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
</person-group><article-title>Astragali radix and its main bioactive compounds activate the Nrf2-mediated signaling pathway to induce P-glycoprotein and breast cancer resistance protein</article-title><source>J. Ethnopharmacol.</source><year>2019</year><volume>228</volume><fpage>82</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2018.09.026</pub-id><pub-id pub-id-type="pmid">30243825</pub-id>
</element-citation></ref><ref id="B37-pharmaceutics-17-00268"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>J.J.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.F.</given-names></name>
<name><surname>Guo</surname><given-names>Z.Z.</given-names></name>
<name><surname>Lou</surname><given-names>Y.M.</given-names></name>
<name><surname>He</surname><given-names>S.G.</given-names></name>
<name><surname>Guan</surname><given-names>Y.</given-names></name>
<name><surname>Zhu</surname><given-names>L.J.</given-names></name>
<name><surname>Liu</surname><given-names>Z.Q.</given-names></name>
<name><surname>Lu</surname><given-names>L.L.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
</person-group><article-title>Aconitum alkaloids, the major components of Aconitum species, affect expression of multidrug resistance-associated protein 2 and breast cancer resistance protein by activating the Nrf2-mediated signalling pathway</article-title><source>Phytomedicine</source><year>2018</year><volume>44</volume><fpage>87</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2017.12.007</pub-id><pub-id pub-id-type="pmid">29277460</pub-id>
</element-citation></ref><ref id="B38-pharmaceutics-17-00268"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McDonald</surname><given-names>J.T.</given-names></name>
<name><surname>Kim</surname><given-names>K.</given-names></name>
<name><surname>Norris</surname><given-names>A.J.</given-names></name>
<name><surname>Vlashi</surname><given-names>E.</given-names></name>
<name><surname>Phillips</surname><given-names>T.M.</given-names></name>
<name><surname>Lagadec</surname><given-names>C.</given-names></name>
<name><surname>Della Donna</surname><given-names>L.</given-names></name>
<name><surname>Ratikan</surname><given-names>J.</given-names></name>
<name><surname>Szelag</surname><given-names>H.</given-names></name>
<name><surname>Hlatky</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Ionizing radiation activates the Nrf2 antioxidant response</article-title><source>Cancer Res.</source><year>2010</year><volume>70</volume><fpage>8886</fpage><lpage>8895</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-0171</pub-id><pub-id pub-id-type="pmid">20940400</pub-id>
</element-citation></ref><ref id="B39-pharmaceutics-17-00268"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chiol&#x000e9;ro</surname><given-names>A.</given-names></name>
<name><surname>Burnier</surname><given-names>M.</given-names></name>
</person-group><article-title>Pharmacology of valsartan, an angiotensin II receptor antagonist</article-title><source>Expert Opin. Investig. Drugs</source><year>1998</year><volume>7</volume><fpage>1915</fpage><lpage>1925</lpage><pub-id pub-id-type="doi">10.1517/13543784.7.11.1915</pub-id></element-citation></ref><ref id="B40-pharmaceutics-17-00268"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamashiro</surname><given-names>W.</given-names></name>
<name><surname>Maeda</surname><given-names>K.</given-names></name>
<name><surname>Hirouchi</surname><given-names>M.</given-names></name>
<name><surname>Adachi</surname><given-names>Y.</given-names></name>
<name><surname>Hu</surname><given-names>Z.</given-names></name>
<name><surname>Sugiyama</surname><given-names>Y.</given-names></name>
</person-group><article-title>Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans</article-title><source>Drug Metab. Dispos.</source><year>2006</year><volume>34</volume><fpage>1247</fpage><lpage>1254</lpage><pub-id pub-id-type="doi">10.1124/dmd.105.008938</pub-id><pub-id pub-id-type="pmid">16624871</pub-id>
</element-citation></ref><ref id="B41-pharmaceutics-17-00268"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arana</surname><given-names>M.R.</given-names></name>
<name><surname>Tocchetti</surname><given-names>G.N.</given-names></name>
<name><surname>Rigalli</surname><given-names>J.P.</given-names></name>
<name><surname>Mottino</surname><given-names>A.D.</given-names></name>
<name><surname>Villanueva</surname><given-names>S.S.</given-names></name>
</person-group><article-title>Physiological and pathophysiological factors affecting the expression and activity of the drug transporter MRP2 in intestine. Impact on its function as membrane barrier</article-title><source>Pharmacol. Res.</source><year>2016</year><volume>109</volume><fpage>32</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2016.04.014</pub-id><pub-id pub-id-type="pmid">27109321</pub-id>
</element-citation></ref><ref id="B42-pharmaceutics-17-00268"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dietrich</surname><given-names>C.G.</given-names></name>
<name><surname>Geier</surname><given-names>A.</given-names></name>
<name><surname>Oude Elferink</surname><given-names>R.P.</given-names></name>
</person-group><article-title>ABC of oral bioavailability: Transporters as gatekeepers in the gut</article-title><source>Gut</source><year>2003</year><volume>52</volume><fpage>1788</fpage><lpage>1795</lpage><pub-id pub-id-type="doi">10.1136/gut.52.12.1788</pub-id><pub-id pub-id-type="pmid">14633964</pub-id>
</element-citation></ref><ref id="B43-pharmaceutics-17-00268"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mottino</surname><given-names>A.D.</given-names></name>
<name><surname>Hoffman</surname><given-names>T.</given-names></name>
<name><surname>Jennes</surname><given-names>L.</given-names></name>
<name><surname>Vore</surname><given-names>M.</given-names></name>
</person-group><article-title>Expression and localization of multidrug resistant protein mrp2 in rat small intestine</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2000</year><volume>293</volume><fpage>717</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1016/S0022-3565(24)39291-2</pub-id><pub-id pub-id-type="pmid">10869369</pub-id>
</element-citation></ref><ref id="B44-pharmaceutics-17-00268"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mazza</surname><given-names>T.</given-names></name>
<name><surname>Roumeliotis</surname><given-names>T.I.</given-names></name>
<name><surname>Garitta</surname><given-names>E.</given-names></name>
<name><surname>Drew</surname><given-names>D.</given-names></name>
<name><surname>Rashid</surname><given-names>S.T.</given-names></name>
<name><surname>Indiveri</surname><given-names>C.</given-names></name>
<name><surname>Choudhary</surname><given-names>J.S.</given-names></name>
<name><surname>Linton</surname><given-names>K.J.</given-names></name>
<name><surname>Beis</surname><given-names>K.</given-names></name>
</person-group><article-title>Structural basis for the modulation of MRP2 activity by phosphorylation and drugs</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><fpage>1983</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-46392-8</pub-id><pub-id pub-id-type="pmid">38438394</pub-id>
</element-citation></ref><ref id="B45-pharmaceutics-17-00268"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suzuki</surname><given-names>H.</given-names></name>
<name><surname>Sugiyama</surname><given-names>Y.</given-names></name>
</person-group><article-title>Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): Its impact on drug disposition</article-title><source>Adv. Drug Deliv. Rev.</source><year>2002</year><volume>54</volume><fpage>1311</fpage><lpage>1331</lpage><pub-id pub-id-type="doi">10.1016/S0169-409X(02)00075-3</pub-id><pub-id pub-id-type="pmid">12406647</pub-id>
</element-citation></ref><ref id="B46-pharmaceutics-17-00268"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>S.</given-names></name>
<name><surname>Kwon</surname><given-names>M.</given-names></name>
<name><surname>Choi</surname><given-names>M.K.</given-names></name>
<name><surname>Song</surname><given-names>I.S.</given-names></name>
</person-group><article-title>Effects of Red Ginseng Extract on the Pharmacokinetics and Elimination of Methotrexate via Mrp2 Regulation</article-title><source>Molecules</source><year>2018</year><volume>23</volume><elocation-id>2948</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23112948</pub-id><pub-id pub-id-type="pmid">30424502</pub-id>
</element-citation></ref><ref id="B47-pharmaceutics-17-00268"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kobayashi</surname><given-names>M.</given-names></name>
<name><surname>Gouda</surname><given-names>K.</given-names></name>
<name><surname>Chisaki</surname><given-names>I.</given-names></name>
<name><surname>Asada</surname><given-names>K.</given-names></name>
<name><surname>Ogura</surname><given-names>J.</given-names></name>
<name><surname>Takahashi</surname><given-names>N.</given-names></name>
<name><surname>Konishi</surname><given-names>T.</given-names></name>
<name><surname>Koshida</surname><given-names>Y.</given-names></name>
<name><surname>Sasaki</surname><given-names>S.</given-names></name>
<name><surname>Yamaguchi</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Regulation of multidrug resistance protein 2 (MRP2, ABCC2) expression by statins: Involvement of SREBP-mediated gene regulation</article-title><source>Int. J. Pharm.</source><year>2013</year><volume>452</volume><fpage>36</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2013.04.019</pub-id><pub-id pub-id-type="pmid">23612356</pub-id>
</element-citation></ref><ref id="B48-pharmaceutics-17-00268"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Du</surname><given-names>T.</given-names></name>
<name><surname>Luo</surname><given-names>T.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Sun</surname><given-names>R.</given-names></name>
<name><surname>Cai</surname><given-names>H.</given-names></name>
</person-group><article-title>Role of MRPs transporters in pharmacokinetics and intestinal toxicity of irinotecan</article-title><source>Food Chem. Toxicol.</source><year>2023</year><volume>182</volume><fpage>114171</fpage><pub-id pub-id-type="doi">10.1016/j.fct.2023.114171</pub-id><pub-id pub-id-type="pmid">37956707</pub-id>
</element-citation></ref><ref id="B49-pharmaceutics-17-00268"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zamek-Gliszczynski</surname><given-names>M.J.</given-names></name>
<name><surname>Hoffmaster</surname><given-names>K.A.</given-names></name>
<name><surname>Tian</surname><given-names>X.</given-names></name>
<name><surname>Zhao</surname><given-names>R.</given-names></name>
<name><surname>Polli</surname><given-names>J.W.</given-names></name>
<name><surname>Humphreys</surname><given-names>J.E.</given-names></name>
<name><surname>Webster</surname><given-names>L.O.</given-names></name>
<name><surname>Bridges</surname><given-names>A.S.</given-names></name>
<name><surname>Kalvass</surname><given-names>J.C.</given-names></name>
<name><surname>Brouwer</surname><given-names>K.L.</given-names></name>
</person-group><article-title>Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: Role of Mrp2 and Bcrp1</article-title><source>Drug Metab. Dispos.</source><year>2005</year><volume>33</volume><fpage>1158</fpage><lpage>1165</lpage><pub-id pub-id-type="doi">10.1124/dmd.104.002188</pub-id><pub-id pub-id-type="pmid">15860656</pub-id>
</element-citation></ref><ref id="B50-pharmaceutics-17-00268"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ge</surname><given-names>S.</given-names></name>
<name><surname>Yin</surname><given-names>T.</given-names></name>
<name><surname>Xu</surname><given-names>B.</given-names></name>
<name><surname>Gao</surname><given-names>S.</given-names></name>
<name><surname>Hu</surname><given-names>M.</given-names></name>
</person-group><article-title>Curcumin Affects Phase II Disposition of Resveratrol Through Inhibiting Efflux Transporters MRP2 and BCRP</article-title><source>Pharm. Res.</source><year>2016</year><volume>33</volume><fpage>590</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1007/s11095-015-1812-1</pub-id><pub-id pub-id-type="pmid">26502886</pub-id>
</element-citation></ref><ref id="B51-pharmaceutics-17-00268"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Feng</surname><given-names>R.</given-names></name>
<name><surname>Wang</surname><given-names>S.S.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Shao</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Link</surname><given-names>F.</given-names></name>
<name><surname>Munker</surname><given-names>S.</given-names></name>
<name><surname>Liebe</surname><given-names>R.</given-names></name>
<name><surname>Meyer</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>FOXA2 prevents hyperbilirubinaemia in acute liver failure by maintaining apical MRP2 expression</article-title><source>Gut</source><year>2023</year><volume>72</volume><fpage>549</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2022-326987</pub-id><pub-id pub-id-type="pmid">35444014</pub-id>
</element-citation></ref><ref id="B52-pharmaceutics-17-00268"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Keppler</surname><given-names>D.</given-names></name>
</person-group><article-title>Export pumps for glutathione S-conjugates</article-title><source>Free Radic. Biol. Med.</source><year>1999</year><volume>27</volume><fpage>985</fpage><lpage>991</lpage><pub-id pub-id-type="doi">10.1016/S0891-5849(99)00171-9</pub-id><pub-id pub-id-type="pmid">10569630</pub-id>
</element-citation></ref><ref id="B53-pharmaceutics-17-00268"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jedlitschky</surname><given-names>G.</given-names></name>
<name><surname>Hoffmann</surname><given-names>U.</given-names></name>
<name><surname>Kroemer</surname><given-names>H.K.</given-names></name>
</person-group><article-title>Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition</article-title><source>Expert Opin. Drug Metab. Toxicol.</source><year>2006</year><volume>2</volume><fpage>351</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1517/17425255.2.3.351</pub-id><pub-id pub-id-type="pmid">16863439</pub-id>
</element-citation></ref><ref id="B54-pharmaceutics-17-00268"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goo</surname><given-names>Y.T.</given-names></name>
<name><surname>Song</surname><given-names>S.H.</given-names></name>
<name><surname>Yeom</surname><given-names>D.W.</given-names></name>
<name><surname>Chae</surname><given-names>B.R.</given-names></name>
<name><surname>Yoon</surname><given-names>H.Y.</given-names></name>
<name><surname>Kim</surname><given-names>C.H.</given-names></name>
<name><surname>Park</surname><given-names>S.Y.</given-names></name>
<name><surname>Kang</surname><given-names>T.H.</given-names></name>
<name><surname>Lee</surname><given-names>S.</given-names></name>
<name><surname>Choi</surname><given-names>Y.W.</given-names></name>
</person-group><article-title>Enhanced oral bioavailability of valsartan in rats using a supersaturable self-microemulsifying drug delivery system with P-glycoprotein inhibitors</article-title><source>Pharm. Dev. Technol.</source><year>2020</year><volume>25</volume><fpage>178</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1080/10837450.2019.1683749</pub-id><pub-id pub-id-type="pmid">31631736</pub-id>
</element-citation></ref><ref id="B55-pharmaceutics-17-00268"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Challa</surname><given-names>V.R.</given-names></name>
<name><surname>Babu</surname><given-names>P.R.</given-names></name>
<name><surname>Challa</surname><given-names>S.R.</given-names></name>
<name><surname>Johnson</surname><given-names>B.</given-names></name>
<name><surname>Maheswari</surname><given-names>C.</given-names></name>
</person-group><article-title>Pharmacokinetic interaction study between quercetin and valsartan in rats and in vitro models</article-title><source>Drug Dev. Ind. Pharm.</source><year>2013</year><volume>39</volume><fpage>865</fpage><lpage>872</lpage><pub-id pub-id-type="doi">10.3109/03639045.2012.693502</pub-id><pub-id pub-id-type="pmid">22670860</pub-id>
</element-citation></ref><ref id="B56-pharmaceutics-17-00268"><label>56.</label><element-citation publication-type="webpage"><article-title>ICH Official Web Site: ICH</article-title><comment>Available online: <ext-link xlink:href="https://www.ich.org/page/multidisciplinary-guidelines" ext-link-type="uri">https://www.ich.org/page/multidisciplinary-guidelines</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-27">(accessed on 27 November 2024)</date-in-citation></element-citation></ref><ref id="B57-pharmaceutics-17-00268"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Niu</surname><given-names>B.</given-names></name>
<name><surname>Liao</surname><given-names>K.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Wen</surname><given-names>T.</given-names></name>
<name><surname>Quan</surname><given-names>G.</given-names></name>
<name><surname>Pan</surname><given-names>X.</given-names></name>
<name><surname>Wu</surname><given-names>C.</given-names></name>
</person-group><article-title>Application of glutathione depletion in cancer therapy: Enhanced ROS-based therapy, ferroptosis, and chemotherapy</article-title><source>Biomaterials</source><year>2021</year><volume>277</volume><elocation-id>121110</elocation-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.121110</pub-id><pub-id pub-id-type="pmid">34482088</pub-id>
</element-citation></ref><ref id="B58-pharmaceutics-17-00268"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hao</surname><given-names>M.</given-names></name>
<name><surname>Liu</surname><given-names>R.</given-names></name>
</person-group><article-title>Molecular mechanism of CAT and SOD activity change under MPA-CdTe quantum dots induced oxidative stress in the mouse primary hepatocytes</article-title><source>Spectrochim. Acta A Mol. Biomol. Spectrosc.</source><year>2019</year><volume>220</volume><elocation-id>117104</elocation-id><pub-id pub-id-type="doi">10.1016/j.saa.2019.05.009</pub-id><pub-id pub-id-type="pmid">31141778</pub-id>
</element-citation></ref><ref id="B59-pharmaceutics-17-00268"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>Y.Y.</given-names></name>
<name><surname>Zhu</surname><given-names>H.J.</given-names></name>
<name><surname>Zhao</surname><given-names>R.Y.</given-names></name>
<name><surname>Zhou</surname><given-names>S.Y.</given-names></name>
<name><surname>Wang</surname><given-names>M.Q.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Guo</surname><given-names>Z.N.</given-names></name>
</person-group><article-title>Remote ischemic conditioning attenuates oxidative stress and inflammation via the Nrf2/HO-1 pathway in MCAO mice</article-title><source>Redox Biol.</source><year>2023</year><volume>66</volume><elocation-id>102852</elocation-id><pub-id pub-id-type="doi">10.1016/j.redox.2023.102852</pub-id><pub-id pub-id-type="pmid">37598463</pub-id>
</element-citation></ref><ref id="B60-pharmaceutics-17-00268"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chunduri</surname><given-names>R.H.</given-names></name>
<name><surname>Dannana</surname><given-names>G.S.</given-names></name>
</person-group><article-title>Development and validation of a reliable and rapid LC-MS/MS method for simultaneous quantification of sacubitril and valsartan in rat plasma and its application to a pharmacokinetic study</article-title><source>Biomed. Chromatogr.</source><year>2016</year><volume>30</volume><fpage>1467</fpage><lpage>1475</lpage><pub-id pub-id-type="doi">10.1002/bmc.3707</pub-id><pub-id pub-id-type="pmid">26876742</pub-id>
</element-citation></ref><ref id="B61-pharmaceutics-17-00268"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>Z.</given-names></name>
<name><surname>Zheng</surname><given-names>X.</given-names></name>
<name><surname>Ding</surname><given-names>C.</given-names></name>
<name><surname>Zou</surname><given-names>Z.</given-names></name>
<name><surname>Liang</surname><given-names>Y.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
</person-group><article-title>Deciphering the Biological Effects of Radiotherapy in Cancer Cells</article-title><source>Biomolecules</source><year>2022</year><volume>12</volume><elocation-id>1167</elocation-id><pub-id pub-id-type="doi">10.3390/biom12091167</pub-id><pub-id pub-id-type="pmid">36139006</pub-id>
</element-citation></ref><ref id="B62-pharmaceutics-17-00268"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kitagawa</surname><given-names>T.</given-names></name>
<name><surname>Yamamoto</surname><given-names>J.</given-names></name>
<name><surname>Tanaka</surname><given-names>T.</given-names></name>
<name><surname>Nakano</surname><given-names>Y.</given-names></name>
<name><surname>Akiba</surname><given-names>D.</given-names></name>
<name><surname>Ueta</surname><given-names>K.</given-names></name>
<name><surname>Nishizawa</surname><given-names>S.</given-names></name>
</person-group><article-title>5-Aminolevulinic acid strongly enhances delayed intracellular production of reactive oxygen species (ROS) generated by ionizing irradiation: Quantitative analyses and visualization of intracellular ROS production in glioma cells in vitro</article-title><source>Oncol. Rep.</source><year>2015</year><volume>33</volume><fpage>583</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.3892/or.2014.3618</pub-id><pub-id pub-id-type="pmid">25420428</pub-id>
</element-citation></ref><ref id="B63-pharmaceutics-17-00268"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Yuan</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>G.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Cheng</surname><given-names>J.</given-names></name>
<name><surname>Lu</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Mitochondrial ROS promote mitochondrial dysfunction and inflammation in ischemic acute kidney injury by disrupting TFAM-mediated mtDNA maintenance</article-title><source>Theranostics</source><year>2021</year><volume>11</volume><fpage>1845</fpage><lpage>1863</lpage><pub-id pub-id-type="doi">10.7150/thno.50905</pub-id><pub-id pub-id-type="pmid">33408785</pub-id>
</element-citation></ref><ref id="B64-pharmaceutics-17-00268"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baskar</surname><given-names>R.</given-names></name>
<name><surname>Lee</surname><given-names>K.A.</given-names></name>
<name><surname>Yeo</surname><given-names>R.</given-names></name>
<name><surname>Yeoh</surname><given-names>K.W.</given-names></name>
</person-group><article-title>Cancer and radiation therapy: Current advances and future directions</article-title><source>Int. J. Med. Sci.</source><year>2012</year><volume>9</volume><fpage>193</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.7150/ijms.3635</pub-id><pub-id pub-id-type="pmid">22408567</pub-id>
</element-citation></ref><ref id="B65-pharmaceutics-17-00268"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Bai</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>R.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Liang</surname><given-names>J.</given-names></name>
<name><surname>Yuan</surname><given-names>Z.</given-names></name>
</person-group><article-title>High versus standard radiation dose of definitive concurrent chemoradiotherapy for esophageal cancer: A systematic review and meta-analysis of randomized clinical trials</article-title><source>Radiother. Oncol.</source><year>2023</year><volume>180</volume><fpage>109463</fpage><pub-id pub-id-type="doi">10.1016/j.radonc.2023.109463</pub-id><pub-id pub-id-type="pmid">36642387</pub-id>
</element-citation></ref><ref id="B66-pharmaceutics-17-00268"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Bissonnette</surname><given-names>J.P.</given-names></name>
<name><surname>Craig</surname><given-names>T.</given-names></name>
<name><surname>Munoz-Schuffenegger</surname><given-names>P.</given-names></name>
<name><surname>Tadic</surname><given-names>T.</given-names></name>
<name><surname>Dawson</surname><given-names>L.A.</given-names></name>
<name><surname>Velec</surname><given-names>M.</given-names></name>
</person-group><article-title>Liver SBRT dose accumulation to assess the impact of anatomic variations on normal tissue doses and toxicity in patients treated with concurrent sorafenib</article-title><source>Radiother. Oncol.</source><year>2023</year><volume>182</volume><fpage>109588</fpage><pub-id pub-id-type="doi">10.1016/j.radonc.2023.109588</pub-id><pub-id pub-id-type="pmid">36858203</pub-id>
</element-citation></ref><ref id="B67-pharmaceutics-17-00268"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Colussi</surname><given-names>D.M.</given-names></name>
<name><surname>Parisot</surname><given-names>C.</given-names></name>
<name><surname>Rossolino</surname><given-names>M.L.</given-names></name>
<name><surname>Brunner</surname><given-names>L.A.</given-names></name>
<name><surname>Lef&#x000e8;vre</surname><given-names>G.Y.</given-names></name>
</person-group><article-title>Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist</article-title><source>J. Clin. Pharmacol.</source><year>1997</year><volume>37</volume><fpage>214</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1002/j.1552-4604.1997.tb04783.x</pub-id><pub-id pub-id-type="pmid">9089423</pub-id>
</element-citation></ref><ref id="B68-pharmaceutics-17-00268"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Waldmeier</surname><given-names>F.</given-names></name>
<name><surname>Flesch</surname><given-names>G.</given-names></name>
<name><surname>M&#x000fc;ller</surname><given-names>P.</given-names></name>
<name><surname>Winkler</surname><given-names>T.</given-names></name>
<name><surname>Kriemler</surname><given-names>H.P.</given-names></name>
<name><surname>B&#x000fc;hlmayer</surname><given-names>P.</given-names></name>
<name><surname>De Gasparo</surname><given-names>M.</given-names></name>
</person-group><article-title>Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose</article-title><source>Xenobiotica</source><year>1997</year><volume>27</volume><fpage>59</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1080/004982597240767</pub-id><pub-id pub-id-type="pmid">9041679</pub-id>
</element-citation></ref><ref id="B69-pharmaceutics-17-00268"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yeom</surname><given-names>D.W.</given-names></name>
<name><surname>Chae</surname><given-names>B.R.</given-names></name>
<name><surname>Son</surname><given-names>H.Y.</given-names></name>
<name><surname>Kim</surname><given-names>J.H.</given-names></name>
<name><surname>Chae</surname><given-names>J.S.</given-names></name>
<name><surname>Song</surname><given-names>S.H.</given-names></name>
<name><surname>Oh</surname><given-names>D.</given-names></name>
<name><surname>Choi</surname><given-names>Y.W.</given-names></name>
</person-group><article-title>Enhanced oral bioavailability of valsartan using a polymer-based supersaturable self-microemulsifying drug delivery system</article-title><source>Int. J. Nanomed.</source><year>2017</year><volume>12</volume><fpage>3533</fpage><lpage>3545</lpage><pub-id pub-id-type="doi">10.2147/IJN.S136599</pub-id></element-citation></ref><ref id="B70-pharmaceutics-17-00268"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arias</surname><given-names>A.</given-names></name>
<name><surname>Rigalli</surname><given-names>J.P.</given-names></name>
<name><surname>Villanueva</surname><given-names>S.S.</given-names></name>
<name><surname>Ruiz</surname><given-names>M.L.</given-names></name>
<name><surname>Luquita</surname><given-names>M.G.</given-names></name>
<name><surname>Perdomo</surname><given-names>V.G.</given-names></name>
<name><surname>Vore</surname><given-names>M.</given-names></name>
<name><surname>Catania</surname><given-names>V.A.</given-names></name>
<name><surname>Mottino</surname><given-names>A.D.</given-names></name>
</person-group><article-title>Regulation of expression and activity of multidrug resistance proteins MRP2 and MDR1 by estrogenic compounds in Caco-2 cells. Role in prevention of xenobiotic-induced cytotoxicity</article-title><source>Toxicology</source><year>2014</year><volume>320</volume><fpage>46</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.tox.2014.03.007</pub-id><pub-id pub-id-type="pmid">24685904</pub-id>
</element-citation></ref><ref id="B71-pharmaceutics-17-00268"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhan</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Fang</surname><given-names>Y.</given-names></name>
<name><surname>Xie</surname><given-names>Y.</given-names></name>
<name><surname>Zheng</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>G.</given-names></name>
<name><surname>Liang</surname><given-names>L.</given-names></name>
<name><surname>Ding</surname><given-names>Y.</given-names></name>
</person-group><article-title>NUPR1 contributes to radiation resistance by maintaining ROS homeostasis via AhR/CYP signal axis in hepatocellular carcinoma</article-title><source>BMC Med.</source><year>2022</year><volume>20</volume><elocation-id>365</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-022-02554-3</pub-id><pub-id pub-id-type="pmid">36258210</pub-id>
</element-citation></ref><ref id="B72-pharmaceutics-17-00268"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xie</surname><given-names>Y.</given-names></name>
<name><surname>Hao</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Guo</surname><given-names>C.</given-names></name>
<name><surname>Kang</surname><given-names>A.</given-names></name>
<name><surname>Wang</surname><given-names>G.</given-names></name>
</person-group><article-title>Reversing effects of lignans on CCl4-induced hepatic CYP450 down regulation by attenuating oxidative stress</article-title><source>J. Ethnopharmacol.</source><year>2014</year><volume>155</volume><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2014.05.016</pub-id><pub-id pub-id-type="pmid">24910408</pub-id>
</element-citation></ref><ref id="B73-pharmaceutics-17-00268"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maher</surname><given-names>J.M.</given-names></name>
<name><surname>Dieter</surname><given-names>M.Z.</given-names></name>
<name><surname>Aleksunes</surname><given-names>L.M.</given-names></name>
<name><surname>Slitt</surname><given-names>A.L.</given-names></name>
<name><surname>Guo</surname><given-names>G.</given-names></name>
<name><surname>Tanaka</surname><given-names>Y.</given-names></name>
<name><surname>Scheffer</surname><given-names>G.L.</given-names></name>
<name><surname>Chan</surname><given-names>J.Y.</given-names></name>
<name><surname>Manautou</surname><given-names>J.E.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway</article-title><source>Hepatology</source><year>2007</year><volume>46</volume><fpage>1597</fpage><lpage>1610</lpage><pub-id pub-id-type="doi">10.1002/hep.21831</pub-id><pub-id pub-id-type="pmid">17668877</pub-id>
</element-citation></ref><ref id="B74-pharmaceutics-17-00268"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>T.</given-names></name>
<name><surname>Jian</surname><given-names>Z.</given-names></name>
<name><surname>Baskys</surname><given-names>A.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Guo</surname><given-names>H.</given-names></name>
<name><surname>Hei</surname><given-names>Y.</given-names></name>
<name><surname>Xian</surname><given-names>P.</given-names></name>
<name><surname>He</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<etal/>
</person-group><article-title>MSC-derived exosomes protect against oxidative stress-induced skin injury via adaptive regulation of the NRF2 defense system</article-title><source>Biomaterials</source><year>2020</year><volume>257</volume><elocation-id>120264</elocation-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2020.120264</pub-id><pub-id pub-id-type="pmid">32791387</pub-id>
</element-citation></ref><ref id="B75-pharmaceutics-17-00268"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Sun</surname><given-names>X.</given-names></name>
<name><surname>Feng</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Fang</surname><given-names>Z.</given-names></name>
<name><surname>Azami</surname><given-names>N.L.B.</given-names></name>
<name><surname>Sun</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>Q.</given-names></name>
</person-group><article-title>Dihydromyricetin reverses MRP2-induced multidrug resistance by preventing NF-&#x003ba;B-Nrf2 signaling in colorectal cancer cell</article-title><source>Phytomedicine</source><year>2021</year><volume>82</volume><fpage>153414</fpage><pub-id pub-id-type="doi">10.1016/j.phymed.2020.153414</pub-id><pub-id pub-id-type="pmid">33461143</pub-id>
</element-citation></ref><ref id="B76-pharmaceutics-17-00268"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schmidlin</surname><given-names>C.J.</given-names></name>
<name><surname>Shakya</surname><given-names>A.</given-names></name>
<name><surname>Dodson</surname><given-names>M.</given-names></name>
<name><surname>Chapman</surname><given-names>E.</given-names></name>
<name><surname>Zhang</surname><given-names>D.D.</given-names></name>
</person-group><article-title>The intricacies of NRF2 regulation in cancer</article-title><source>Semin. Cancer Biol.</source><year>2021</year><volume>76</volume><fpage>110</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2021.05.016</pub-id><pub-id pub-id-type="pmid">34020028</pub-id>
</element-citation></ref><ref id="B77-pharmaceutics-17-00268"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Namani</surname><given-names>A.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>X.J.</given-names></name>
<name><surname>Tang</surname><given-names>X.</given-names></name>
</person-group><article-title>Modulation of NRF2 signaling pathway by nuclear receptors: Implications for cancer</article-title><source>Biochim. Biophys. Acta (BBA) Mol. Cell Res.</source><year>2014</year><volume>1843</volume><fpage>1875</fpage><lpage>1885</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2014.05.003</pub-id></element-citation></ref><ref id="B78-pharmaceutics-17-00268"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>T.</given-names></name>
<name><surname>Lv</surname><given-names>Y.F.</given-names></name>
<name><surname>Zhao</surname><given-names>J.L.</given-names></name>
<name><surname>You</surname><given-names>Q.D.</given-names></name>
<name><surname>Jiang</surname><given-names>Z.Y.</given-names></name>
</person-group><article-title>Regulation of Nrf2 by phosphorylation: Consequences for biological function and therapeutic implications</article-title><source>Free Radic. Biol. Med.</source><year>2021</year><volume>168</volume><fpage>129</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2021.03.034</pub-id><pub-id pub-id-type="pmid">33794311</pub-id>
</element-citation></ref><ref id="B79-pharmaceutics-17-00268"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Turpaev</surname><given-names>K.T.</given-names></name>
</person-group><article-title>Keap1-Nrf2 signaling pathway: Mechanisms of regulation and role in protection of cells against toxicity caused by xenobiotics and electrophiles</article-title><source>Biochemistry</source><year>2013</year><volume>78</volume><fpage>111</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1134/S0006297913020016</pub-id><pub-id pub-id-type="pmid">23581983</pub-id>
</element-citation></ref><ref id="B80-pharmaceutics-17-00268"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sivandzade</surname><given-names>F.</given-names></name>
<name><surname>Prasad</surname><given-names>S.</given-names></name>
<name><surname>Bhalerao</surname><given-names>A.</given-names></name>
<name><surname>Cucullo</surname><given-names>L.</given-names></name>
</person-group><article-title>NRF2 and NF-&#x003ba;B interplay in cerebrovascular and neurodegenerative disorders: Molecular mechanisms and possible therapeutic approaches</article-title><source>Redox Biol.</source><year>2019</year><volume>21</volume><elocation-id>101059</elocation-id><pub-id pub-id-type="doi">10.1016/j.redox.2018.11.017</pub-id><pub-id pub-id-type="pmid">30576920</pub-id>
</element-citation></ref><ref id="B81-pharmaceutics-17-00268"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Diao</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>N.</given-names></name>
<name><surname>Brayman</surname><given-names>T.G.</given-names></name>
<name><surname>Hotz</surname><given-names>K.J.</given-names></name>
<name><surname>Lai</surname><given-names>Y.</given-names></name>
</person-group><article-title>Regulation of MRP2/ABCC2 and BSEP/ABCB11 expression in sandwich cultured human and rat hepatocytes exposed to inflammatory cytokines TNF-&#x003b1;, IL-6, and IL-1&#x003b2;</article-title><source>J. Biol. Chem.</source><year>2010</year><volume>285</volume><fpage>31185</fpage><lpage>31192</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.107805</pub-id><pub-id pub-id-type="pmid">20702406</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-17-00268-f001"><label>Figure 1</label><caption><p>The average blood concentration&#x02013;time (0&#x02013;4 h) curve of valsartan (<bold>A</bold>) and logarithmic average blood concentration&#x02013;time (0&#x02013;24 h) curve of valsartan (<bold>B</bold>) in rats after abdominal irradiation with 5 Gy of X-rays (Mean &#x000b1; SD, <italic toggle="yes">n</italic> = 6, * indicates the control group compared, * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01).</p></caption><graphic xlink:href="pharmaceutics-17-00268-g001" position="float"/></fig><fig position="float" id="pharmaceutics-17-00268-f002"><label>Figure 2</label><caption><p>The cumulative excretion fraction of valsartan in bile (<bold>A</bold>), fecal (<bold>C</bold>), urine (<bold>D</bold>), and excretion fraction of valsartan in different time periods in bile (<bold>B</bold>) after abdominal irradiation with 5 Gy of X-rays (Mean &#x000b1; SD, <italic toggle="yes">n</italic> = 4( <bold>A</bold>,<bold>B</bold>), <italic toggle="yes">n</italic> = 6 (<bold>C</bold>,<bold>D</bold>); * indicates the control group compared, * <italic toggle="yes">p</italic> &#x0003c; 0.05).</p></caption><graphic xlink:href="pharmaceutics-17-00268-g002" position="float"/></fig><fig position="float" id="pharmaceutics-17-00268-f003"><label>Figure 3</label><caption><p>Absorption of valsartan after abdominal irradiation with 5 Gy of X-rays in inverted intestine sac (Mean &#x000b1; SD, <italic toggle="yes">n</italic> = 6, * indicates the control group compared, * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01).</p></caption><graphic xlink:href="pharmaceutics-17-00268-g003" position="float"/></fig><fig position="float" id="pharmaceutics-17-00268-f004"><label>Figure 4</label><caption><p>Percentage of Caco-2 viability after treatment with valsartan and inhibitors of Mrp2 and P-gp (<bold>A</bold>), concentration of valsartan in Caco-2 cells after treatment with valsartan and inhibitors of MK571 or Ver (<bold>B</bold>), and concentration of valsartan in Caco-2 cells after irradiation with 5 Gy of X-rays (<bold>C</bold>) (Mean &#x000b1; SD, <italic toggle="yes">n</italic> = 4, * indicates the control group compared, # indicates the MK571 group compared, * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01, *** <italic toggle="yes">p</italic> &#x0003c; 0.001, # <italic toggle="yes">p</italic> &#x0003c; 0.05, ## <italic toggle="yes">p</italic> &#x0003c; 0.01, ### <italic toggle="yes">p</italic> &#x0003c; 0.001).</p></caption><graphic xlink:href="pharmaceutics-17-00268-g004" position="float"/></fig><fig position="float" id="pharmaceutics-17-00268-f005"><label>Figure 5</label><caption><p>Relative mRNA expression of Mrp2/&#x003b2;-actin (<bold>A</bold>) and P-gp/&#x003b2;-actin (<bold>B</bold>) in rat intestine; Mrp2/&#x003b2;-actin (<bold>C</bold>) and P-gp/&#x003b2;-actin (<bold>D</bold>) in Caco-2 cells after irradiation with 5 Gy of X-rays (Mean &#x000b1; SD, <italic toggle="yes">n</italic> = 4, * indicates the control group compared, * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01, *** <italic toggle="yes">p</italic> &#x0003c; 0.001).</p></caption><graphic xlink:href="pharmaceutics-17-00268-g005" position="float"/></fig><fig position="float" id="pharmaceutics-17-00268-f006"><label>Figure 6</label><caption><p>Effect of irradiation with 5 Gy X-ray on concentration of GSH (<bold>A</bold>), SOD activity (<bold>B</bold>), and CAT activity (<bold>C</bold>) in rat jejunum (Mean &#x000b1; SD, <italic toggle="yes">n</italic> = 4, * indicates the control group compared, * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01, *** <italic toggle="yes">p</italic> &#x0003c; 0.001).</p></caption><graphic xlink:href="pharmaceutics-17-00268-g006" position="float"/></fig><fig position="float" id="pharmaceutics-17-00268-f007"><label>Figure 7</label><caption><p>Relative mRNA expression of Nrf2/&#x003b2;-actin (<bold>A</bold>) and HO-1/&#x003b2;-actin (<bold>B</bold>) in rat intestine after irradiation with 5 Gy of X-rays (Mean &#x000b1; SD, <italic toggle="yes">n</italic> = 4, * indicates the control group compared, * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01).</p></caption><graphic xlink:href="pharmaceutics-17-00268-g007" position="float"/></fig><fig position="float" id="pharmaceutics-17-00268-f008"><label>Figure 8</label><caption><p>X-ray irradiation induces oxidative stress and upregulates intestinal Nrf2-Mrp2, leading to decreased intestinal absorption of valsartan.</p></caption><graphic xlink:href="pharmaceutics-17-00268-g008" position="float"/></fig><table-wrap position="float" id="pharmaceutics-17-00268-t001"><object-id pub-id-type="pii">pharmaceutics-17-00268-t001_Table 1</object-id><label>Table 1</label><caption><p>The pharmacokinetic parameters of valsartan in rat plasma after abdominal irradiation with 5 Gy of X-rays (Mean &#x000b1; SD, <italic toggle="yes">n</italic> = 6, * indicates the control group compared, * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Parameter</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Control</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IR-5 Gy</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">t<bold><sub>1/2</sub></bold></td><td align="center" valign="middle" rowspan="1" colspan="1">h</td><td align="center" valign="middle" rowspan="1" colspan="1">3.568 &#x000b1; 0.411</td><td align="center" valign="middle" rowspan="1" colspan="1">5.032 &#x000b1; 2.656</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">C<sub>max</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">ng/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">4428.333 &#x000b1; 1261.656</td><td align="center" valign="middle" rowspan="1" colspan="1">2131.667 &#x000b1; 877.802 **</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">T<sub>max</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">h</td><td align="center" valign="middle" rowspan="1" colspan="1">0.250 &#x000b1; 0.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.222 &#x000b1; 0.068</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AUC<sub>0&#x02013;24h</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">ng&#x000b7;h/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">8456.466 &#x000b1; 1840.136</td><td align="center" valign="middle" rowspan="1" colspan="1">5269.367 &#x000b1; 1826.438 *</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AUC<sub>0&#x02013;&#x0221e;</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">ng&#x000b7;h/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">8813.281 &#x000b1; 2011.750</td><td align="center" valign="middle" rowspan="1" colspan="1">5469.390 &#x000b1; 1791.823 *</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V<sub>d</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">L/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">6.254 &#x000b1; 2.349</td><td align="center" valign="middle" rowspan="1" colspan="1">14.668 &#x000b1; 9.456</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CL</td><td align="center" valign="middle" rowspan="1" colspan="1">L/h/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">1.200 &#x000b1; 0.352</td><td align="center" valign="middle" rowspan="1" colspan="1">2.120 &#x000b1; 1.110</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MRT<sub>0&#x02013;24h</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.839 &#x000b1; 0.724</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.521 &#x000b1; 1.631</td></tr></tbody></table></table-wrap></floats-group></article>